WO2015168416A1 - Methods for determination of bioactivity, removal, or inactivation cereal amylase trypsin inhibitors in cereals, flours and complex foods - Google Patents
Methods for determination of bioactivity, removal, or inactivation cereal amylase trypsin inhibitors in cereals, flours and complex foods Download PDFInfo
- Publication number
- WO2015168416A1 WO2015168416A1 PCT/US2015/028535 US2015028535W WO2015168416A1 WO 2015168416 A1 WO2015168416 A1 WO 2015168416A1 US 2015028535 W US2015028535 W US 2015028535W WO 2015168416 A1 WO2015168416 A1 WO 2015168416A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- ati
- foodstuff
- atis
- cells
- buffer
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 119
- 239000004382 Amylase Substances 0.000 title claims abstract description 8
- 102000013142 Amylases Human genes 0.000 title claims abstract description 8
- 108010065511 Amylases Proteins 0.000 title claims abstract description 8
- 235000019418 amylase Nutrition 0.000 title claims abstract description 8
- 239000002753 trypsin inhibitor Substances 0.000 title claims abstract description 8
- 235000013339 cereals Nutrition 0.000 title claims description 21
- 235000013305 food Nutrition 0.000 title description 43
- 235000013312 flour Nutrition 0.000 title description 23
- 230000002779 inactivation Effects 0.000 title description 9
- 210000004027 cell Anatomy 0.000 claims description 61
- 239000000284 extract Substances 0.000 claims description 48
- 108090000623 proteins and genes Proteins 0.000 claims description 37
- 239000000872 buffer Substances 0.000 claims description 35
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 33
- 235000018102 proteins Nutrition 0.000 claims description 33
- 102000004169 proteins and genes Human genes 0.000 claims description 33
- 239000011536 extraction buffer Substances 0.000 claims description 31
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 30
- 108010068370 Glutens Proteins 0.000 claims description 26
- 238000000605 extraction Methods 0.000 claims description 26
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims description 24
- 235000021312 gluten Nutrition 0.000 claims description 23
- 239000003638 chemical reducing agent Substances 0.000 claims description 20
- 239000006228 supernatant Substances 0.000 claims description 20
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 claims description 19
- 102100039360 Toll-like receptor 4 Human genes 0.000 claims description 19
- 239000003599 detergent Substances 0.000 claims description 19
- 230000004044 response Effects 0.000 claims description 19
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 claims description 18
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 claims description 18
- 235000012538 ammonium bicarbonate Nutrition 0.000 claims description 18
- 239000001099 ammonium carbonate Substances 0.000 claims description 18
- 239000000203 mixture Substances 0.000 claims description 18
- 108091005804 Peptidases Proteins 0.000 claims description 17
- 239000012588 trypsin Substances 0.000 claims description 17
- 108090000631 Trypsin Proteins 0.000 claims description 16
- 102000004142 Trypsin Human genes 0.000 claims description 16
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 15
- 230000007935 neutral effect Effects 0.000 claims description 15
- 239000002953 phosphate buffered saline Substances 0.000 claims description 15
- 229960001322 trypsin Drugs 0.000 claims description 15
- 239000004365 Protease Substances 0.000 claims description 14
- 230000004913 activation Effects 0.000 claims description 14
- 230000029087 digestion Effects 0.000 claims description 14
- 238000011002 quantification Methods 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 108010053070 Glutathione Disulfide Proteins 0.000 claims description 13
- YPZRWBKMTBYPTK-BJDJZHNGSA-N glutathione disulfide Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(O)=O)CSSC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O YPZRWBKMTBYPTK-BJDJZHNGSA-N 0.000 claims description 13
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 12
- 102000004127 Cytokines Human genes 0.000 claims description 12
- 108090000695 Cytokines Proteins 0.000 claims description 12
- 108090001007 Interleukin-8 Proteins 0.000 claims description 12
- 102000004890 Interleukin-8 Human genes 0.000 claims description 12
- 229960003180 glutathione Drugs 0.000 claims description 12
- 239000002904 solvent Substances 0.000 claims description 12
- 102100021943 C-C motif chemokine 2 Human genes 0.000 claims description 11
- VHJLVAABSRFDPM-ZXZARUISSA-N dithioerythritol Chemical compound SC[C@H](O)[C@H](O)CS VHJLVAABSRFDPM-ZXZARUISSA-N 0.000 claims description 11
- 238000011534 incubation Methods 0.000 claims description 11
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 claims description 10
- 238000001035 drying Methods 0.000 claims description 10
- 238000004949 mass spectrometry Methods 0.000 claims description 10
- 108090000284 Pepsin A Proteins 0.000 claims description 9
- 102000057297 Pepsin A Human genes 0.000 claims description 9
- 239000002168 alkylating agent Substances 0.000 claims description 9
- 229940100198 alkylating agent Drugs 0.000 claims description 9
- 229940111202 pepsin Drugs 0.000 claims description 9
- 241000894006 Bacteria Species 0.000 claims description 8
- 238000002965 ELISA Methods 0.000 claims description 8
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 8
- 239000008188 pellet Substances 0.000 claims description 8
- 101710155857 C-C motif chemokine 2 Proteins 0.000 claims description 7
- 102100032367 C-C motif chemokine 5 Human genes 0.000 claims description 7
- 108010024636 Glutathione Proteins 0.000 claims description 7
- 241000186604 Lactobacillus reuteri Species 0.000 claims description 7
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 7
- 238000000502 dialysis Methods 0.000 claims description 7
- PGLTVOMIXTUURA-UHFFFAOYSA-N iodoacetamide Chemical group NC(=O)CI PGLTVOMIXTUURA-UHFFFAOYSA-N 0.000 claims description 7
- 210000002540 macrophage Anatomy 0.000 claims description 7
- 238000001262 western blot Methods 0.000 claims description 7
- YONJPLIBVIENNO-LAEOZQHASA-N (2s)-2-amino-5-[[(2r)-3-[(1s)-1-amino-1-carboxy-2-methylpropan-2-yl]sulfanyl-1-(carboxymethylamino)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid Chemical compound OC(=O)[C@H](N)C(C)(C)SC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O YONJPLIBVIENNO-LAEOZQHASA-N 0.000 claims description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 6
- 108090000317 Chymotrypsin Proteins 0.000 claims description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- 108700008625 Reporter Genes Proteins 0.000 claims description 6
- 229960002376 chymotrypsin Drugs 0.000 claims description 6
- 210000004443 dendritic cell Anatomy 0.000 claims description 6
- 238000001514 detection method Methods 0.000 claims description 6
- YPZRWBKMTBYPTK-UHFFFAOYSA-N oxidized gamma-L-glutamyl-L-cysteinylglycine Natural products OC(=O)C(N)CCC(=O)NC(C(=O)NCC(O)=O)CSSCC(C(=O)NCC(O)=O)NC(=O)CCC(N)C(O)=O YPZRWBKMTBYPTK-UHFFFAOYSA-N 0.000 claims description 6
- 108700034543 penicillamine-glutathione mixed disulfide Proteins 0.000 claims description 6
- 230000019491 signal transduction Effects 0.000 claims description 6
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 5
- 235000013864 Lactobacillus sanfrancisco Nutrition 0.000 claims description 5
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 5
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 5
- 239000007983 Tris buffer Substances 0.000 claims description 5
- 239000013504 Triton X-100 Substances 0.000 claims description 5
- 229920004890 Triton X-100 Polymers 0.000 claims description 5
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 5
- 235000018417 cysteine Nutrition 0.000 claims description 5
- 229960003964 deoxycholic acid Drugs 0.000 claims description 5
- 229960004132 diethyl ether Drugs 0.000 claims description 5
- 238000000684 flow cytometry Methods 0.000 claims description 5
- 210000001616 monocyte Anatomy 0.000 claims description 5
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 5
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 5
- 229940083575 sodium dodecyl sulfate Drugs 0.000 claims description 5
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 5
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 5
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 claims description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 4
- 101100507655 Canis lupus familiaris HSPA1 gene Proteins 0.000 claims description 4
- 108010055166 Chemokine CCL5 Proteins 0.000 claims description 4
- 101100339887 Drosophila melanogaster Hsp27 gene Proteins 0.000 claims description 4
- 101150096895 HSPB1 gene Proteins 0.000 claims description 4
- 102100034051 Heat shock protein HSP 90-alpha Human genes 0.000 claims description 4
- 101001016865 Homo sapiens Heat shock protein HSP 90-alpha Proteins 0.000 claims description 4
- 108010058846 Ovalbumin Proteins 0.000 claims description 4
- 108700012920 TNF Proteins 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 4
- 230000004075 alteration Effects 0.000 claims description 4
- 238000009835 boiling Methods 0.000 claims description 4
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 claims description 4
- 238000004108 freeze drying Methods 0.000 claims description 4
- 239000003960 organic solvent Substances 0.000 claims description 4
- 229940092253 ovalbumin Drugs 0.000 claims description 4
- 230000009257 reactivity Effects 0.000 claims description 4
- 230000011664 signaling Effects 0.000 claims description 4
- 229910052717 sulfur Inorganic materials 0.000 claims description 4
- 239000011593 sulfur Substances 0.000 claims description 4
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims description 3
- 101000797762 Homo sapiens C-C motif chemokine 5 Proteins 0.000 claims description 3
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims description 3
- 102000008070 Interferon-gamma Human genes 0.000 claims description 3
- 108010074328 Interferon-gamma Proteins 0.000 claims description 3
- 102000003812 Interleukin-15 Human genes 0.000 claims description 3
- 108090000172 Interleukin-15 Proteins 0.000 claims description 3
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims description 3
- 108090001109 Thermolysin Proteins 0.000 claims description 3
- 210000000612 antigen-presenting cell Anatomy 0.000 claims description 3
- JYYOBHFYCIDXHH-UHFFFAOYSA-N carbonic acid;hydrate Chemical compound O.OC(O)=O JYYOBHFYCIDXHH-UHFFFAOYSA-N 0.000 claims description 3
- 239000003337 fertilizer Substances 0.000 claims description 3
- 229960003130 interferon gamma Drugs 0.000 claims description 3
- 230000003834 intracellular effect Effects 0.000 claims description 3
- 230000005937 nuclear translocation Effects 0.000 claims description 3
- 230000035755 proliferation Effects 0.000 claims description 3
- 101000897480 Homo sapiens C-C motif chemokine 2 Proteins 0.000 claims description 2
- 108010047357 Luminescent Proteins Proteins 0.000 claims description 2
- 102000006830 Luminescent Proteins Human genes 0.000 claims description 2
- 238000007605 air drying Methods 0.000 claims description 2
- 239000003125 aqueous solvent Substances 0.000 claims description 2
- 108091006047 fluorescent proteins Proteins 0.000 claims description 2
- 102000034287 fluorescent proteins Human genes 0.000 claims description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 5
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 claims 2
- 241000186868 Lactobacillus sanfranciscensis Species 0.000 claims 1
- 241000209140 Triticum Species 0.000 description 35
- 235000021307 Triticum Nutrition 0.000 description 34
- 238000000855 fermentation Methods 0.000 description 21
- 230000004151 fermentation Effects 0.000 description 21
- 230000002829 reductive effect Effects 0.000 description 18
- 235000007238 Secale cereale Nutrition 0.000 description 16
- 230000000694 effects Effects 0.000 description 16
- 235000006171 gluten free diet Nutrition 0.000 description 15
- 235000020884 gluten-free diet Nutrition 0.000 description 15
- 230000002797 proteolythic effect Effects 0.000 description 15
- 102000035195 Peptidases Human genes 0.000 description 12
- 241000209219 Hordeum Species 0.000 description 10
- 235000007340 Hordeum vulgare Nutrition 0.000 description 10
- 235000005911 diet Nutrition 0.000 description 10
- 230000037213 diet Effects 0.000 description 10
- 239000002158 endotoxin Substances 0.000 description 10
- 229920006008 lipopolysaccharide Polymers 0.000 description 10
- 238000006722 reduction reaction Methods 0.000 description 10
- 238000003556 assay Methods 0.000 description 9
- 239000005018 casein Substances 0.000 description 9
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 9
- 235000021240 caseins Nutrition 0.000 description 9
- 230000009467 reduction Effects 0.000 description 9
- 230000006698 induction Effects 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- 208000015943 Coeliac disease Diseases 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 244000025090 Lactobacillus sanfrancisco Species 0.000 description 7
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 7
- 229940088598 enzyme Drugs 0.000 description 7
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- 241000894007 species Species 0.000 description 7
- 238000011740 C57BL/6 mouse Methods 0.000 description 6
- 241000196324 Embryophyta Species 0.000 description 6
- 241000186660 Lactobacillus Species 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 230000002378 acidificating effect Effects 0.000 description 5
- 238000005119 centrifugation Methods 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 230000000968 intestinal effect Effects 0.000 description 5
- 210000000936 intestine Anatomy 0.000 description 5
- 230000004936 stimulating effect Effects 0.000 description 5
- 108010012236 Chemokines Proteins 0.000 description 4
- 102000019034 Chemokines Human genes 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 108010026552 Proteome Proteins 0.000 description 4
- 239000005864 Sulphur Substances 0.000 description 4
- 208000006673 asthma Diseases 0.000 description 4
- 230000000975 bioactive effect Effects 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 201000002491 encephalomyelitis Diseases 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 235000016709 nutrition Nutrition 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 108010061711 Gliadin Proteins 0.000 description 3
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 3
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 3
- 241001529936 Murinae Species 0.000 description 3
- 206010033799 Paralysis Diseases 0.000 description 3
- 108700039882 Protein Glutamine gamma Glutamyltransferase 2 Proteins 0.000 description 3
- 102100038095 Protein-glutamine gamma-glutamyltransferase 2 Human genes 0.000 description 3
- 241000191043 Rhodobacter sphaeroides Species 0.000 description 3
- 241000209056 Secale Species 0.000 description 3
- 206010070834 Sensitisation Diseases 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 102100040247 Tumor necrosis factor Human genes 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- 238000004166 bioassay Methods 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 238000001516 cell proliferation assay Methods 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 229920003045 dextran sodium sulfate Polymers 0.000 description 3
- 150000002019 disulfides Chemical class 0.000 description 3
- -1 e.g. Proteins 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 201000006417 multiple sclerosis Diseases 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 230000017854 proteolysis Effects 0.000 description 3
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 3
- 235000021067 refined food Nutrition 0.000 description 3
- 238000003757 reverse transcription PCR Methods 0.000 description 3
- FHHPUSMSKHSNKW-SMOYURAASA-M sodium deoxycholate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 FHHPUSMSKHSNKW-SMOYURAASA-M 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 230000010777 Disulfide Reduction Effects 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 2
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
- 241000186612 Lactobacillus sakei Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 108090000787 Subtilisin Proteins 0.000 description 2
- 230000006052 T cell proliferation Effects 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 230000029936 alkylation Effects 0.000 description 2
- 238000005804 alkylation reaction Methods 0.000 description 2
- 201000009961 allergic asthma Diseases 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 230000003042 antagnostic effect Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 206010009887 colitis Diseases 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000006334 disulfide bridging Effects 0.000 description 2
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 230000004720 fertilization Effects 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 208000010726 hind limb paralysis Diseases 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 230000005934 immune activation Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000015788 innate immune response Effects 0.000 description 2
- 229940001882 lactobacillus reuteri Drugs 0.000 description 2
- 210000003141 lower extremity Anatomy 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 230000031787 nutrient reservoir activity Effects 0.000 description 2
- 235000015927 pasta Nutrition 0.000 description 2
- 230000000243 photosynthetic effect Effects 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 210000004988 splenocyte Anatomy 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 125000003396 thiol group Chemical group [H]S* 0.000 description 2
- 150000003573 thiols Chemical class 0.000 description 2
- 230000003827 upregulation Effects 0.000 description 2
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 description 1
- 229930014124 (-)-epigallocatechin gallate Natural products 0.000 description 1
- OQWKEEOHDMUXEO-UHFFFAOYSA-N (6)-shogaol Natural products CCCCCC=CC(=O)CCC1=CC=C(O)C(OC)=C1 OQWKEEOHDMUXEO-UHFFFAOYSA-N 0.000 description 1
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 102000004580 Aspartic Acid Proteases Human genes 0.000 description 1
- 108010017640 Aspartic Acid Proteases Proteins 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 1
- 108090000145 Bacillolysin Proteins 0.000 description 1
- 241000606108 Bartonella quintana Species 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 102100035882 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 101710171837 Chymotrypsin inhibitor WCI Proteins 0.000 description 1
- 241000723363 Clerodendrum Species 0.000 description 1
- 108010026206 Conalbumin Proteins 0.000 description 1
- 102000020018 Cystathionine gamma-Lyase Human genes 0.000 description 1
- 108010045283 Cystathionine gamma-lyase Proteins 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 238000001061 Dunnett's test Methods 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 101710082899 Endogenous alpha-amylase/subtilisin inhibitor Proteins 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- 244000246838 Falcataria moluccana Species 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 description 1
- 206010017577 Gait disturbance Diseases 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 108010063907 Glutathione Reductase Proteins 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 108010047762 HLA-DQ8 antigen Proteins 0.000 description 1
- 101000606113 Homo sapiens Tyrosine 3-monooxygenase Proteins 0.000 description 1
- 102000000743 Interleukin-5 Human genes 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 102000043129 MHC class I family Human genes 0.000 description 1
- 108091054437 MHC class I family Proteins 0.000 description 1
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 description 1
- 108010083674 Myelin Proteins Proteins 0.000 description 1
- 102000006386 Myelin Proteins Human genes 0.000 description 1
- 102100023302 Myelin-oligodendrocyte glycoprotein Human genes 0.000 description 1
- 108091005507 Neutral proteases Proteins 0.000 description 1
- 102000035092 Neutral proteases Human genes 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 108010081690 Pertussis Toxin Proteins 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 241000435574 Popa Species 0.000 description 1
- 241000605862 Porphyromonas gingivalis Species 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 108010052090 Renilla Luciferases Proteins 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 102100036407 Thioredoxin Human genes 0.000 description 1
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 1
- 235000007264 Triticum durum Nutrition 0.000 description 1
- 240000002805 Triticum turgidum Species 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 244000273928 Zingiber officinale Species 0.000 description 1
- 235000006886 Zingiber officinale Nutrition 0.000 description 1
- OQWKEEOHDMUXEO-BQYQJAHWSA-N [6]-Shogaol Chemical compound CCCCC\C=C\C(=O)CCC1=CC=C(O)C(OC)=C1 OQWKEEOHDMUXEO-BQYQJAHWSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 230000004721 adaptive immunity Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000000240 adjuvant effect Effects 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 102000004139 alpha-Amylases Human genes 0.000 description 1
- 108090000637 alpha-Amylases Proteins 0.000 description 1
- 229940024171 alpha-amylase Drugs 0.000 description 1
- 239000003392 amylase inhibitor Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 150000001491 aromatic compounds Chemical class 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 235000015173 baked goods and baking mixes Nutrition 0.000 description 1
- 229940092523 bartonella quintana Drugs 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- YBHILYKTIRIUTE-UHFFFAOYSA-N berberine Chemical compound C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 YBHILYKTIRIUTE-UHFFFAOYSA-N 0.000 description 1
- AFYNADDZULBEJA-UHFFFAOYSA-N bicinchoninic acid Chemical compound C1=CC=CC2=NC(C=3C=C(C4=CC=CC=C4N=3)C(=O)O)=CC(C(O)=O)=C21 AFYNADDZULBEJA-UHFFFAOYSA-N 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 239000004464 cereal grain Substances 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 1
- 235000020230 cinnamon extract Nutrition 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 230000009266 disease activity Effects 0.000 description 1
- 125000002228 disulfide group Chemical group 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- BPSMYQFMCXXNPC-MFCPCZTFSA-N eritoran Chemical compound O[C@H]1[C@H](OCCCCCCCCCC)[C@@H](NC(=O)CC(=O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O[C@@H]1CO[C@H]1[C@H](NC(=O)CCCCCCCCC\C=C/CCCCCC)[C@@H](OCC[C@@H](CCCCCCC)OC)[C@H](OP(O)(O)=O)[C@@H](COC)O1 BPSMYQFMCXXNPC-MFCPCZTFSA-N 0.000 description 1
- 229950007107 eritoran Drugs 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 208000012997 experimental autoimmune encephalomyelitis Diseases 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000012470 frozen dough Nutrition 0.000 description 1
- 239000000446 fuel Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000012252 genetic analysis Methods 0.000 description 1
- 238000012268 genome sequencing Methods 0.000 description 1
- 235000008397 ginger Nutrition 0.000 description 1
- SYUXAJSOZXEFPP-UHFFFAOYSA-N glutin Natural products COc1c(O)cc2OC(=CC(=O)c2c1O)c3ccccc3OC4OC(CO)C(O)C(O)C4O SYUXAJSOZXEFPP-UHFFFAOYSA-N 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 235000009569 green tea Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 208000027905 limb weakness Diseases 0.000 description 1
- 231100000861 limb weakness Toxicity 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229960003987 melatonin Drugs 0.000 description 1
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000005012 myelin Anatomy 0.000 description 1
- YFCUZWYIPBUQBD-ZOWNYOTGSA-N n-[(3s)-7-amino-1-chloro-2-oxoheptan-3-yl]-4-methylbenzenesulfonamide;hydron;chloride Chemical compound Cl.CC1=CC=C(S(=O)(=O)N[C@@H](CCCCN)C(=O)CCl)C=C1 YFCUZWYIPBUQBD-ZOWNYOTGSA-N 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000004248 oligodendroglia Anatomy 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 150000002926 oxygen Chemical class 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 208000010713 partial hind limb paralysis Diseases 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 231100000683 possible toxicity Toxicity 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000003244 pro-oxidative effect Effects 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 238000012207 quantitative assay Methods 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000028527 righting reflex Effects 0.000 description 1
- 238000005185 salting out Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 108060008226 thioredoxin Proteins 0.000 description 1
- 229940094937 thioredoxin Drugs 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000012794 white bread Nutrition 0.000 description 1
- 235000011844 whole wheat flour Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L5/00—Preparation or treatment of foods or foodstuffs, in general; Food or foodstuffs obtained thereby; Materials therefor
- A23L5/20—Removal of unwanted matter, e.g. deodorisation or detoxification
- A23L5/28—Removal of unwanted matter, e.g. deodorisation or detoxification using microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L5/00—Preparation or treatment of foods or foodstuffs, in general; Food or foodstuffs obtained thereby; Materials therefor
- A23L5/20—Removal of unwanted matter, e.g. deodorisation or detoxification
- A23L5/23—Removal of unwanted matter, e.g. deodorisation or detoxification by extraction with solvents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/173—Reuteri
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/183—Sanfranciscenis
Definitions
- ATIs alpha-amylase/trypsin inhibitors
- ATIs then elicit release of proinflammatory cytokines from cells inceliac and non-celiac patients. Mice deficient in TLR4 or TLR4 signaling are protected from intestinal and systemic immune responses upon oral challenge with ATIs. These findings define cereal ATIs as contributors to celiac disease. Moreover, ATIs may fuel inflammation and immune reactions in other intestinal and non-intestinal immune disorders. There exists a need for novel technologies and methods that are able to remove ATI from foods.
- the present invention features methods of extracting ATIs from processed and unprocessed foodstuff, determining bioactivity of ATIs, qualifying the amount of ATIs in a foodstuff, and reducing the content of ATIs in a foodstuff.
- the invention features a method of extracting amylase trypsin inhibitors (ATIs) from a foodstuff.
- the method includes the steps of A) incubating the foodstuff with an extraction buffer in a mixture, B) centrifuging the mixture to form a pellet and supernatant, C) drying the supernatant, and D) reconstituting the dried supernatant in a reconstitution buffer.
- the extracted ATIs are present in the reconstitution buffer.
- the foodstuff is unprocessed prior to extraction.
- the foodstuff is a processed foodstuff.
- the foodstuff prior to incubating the foodstuff with an extraction buffer in a mixture, the foodstuff is ground.
- the foodstuff prior to incubating the foodstuff with an extraction buffer in a mixture, is defatted. Particularly, the defatting is performed by the incubation of the foodstuff with methanol/diethylether (e.g., at a 1 :1 ratio).
- the extraction buffer is ammonium bicarbonate, chloroform/methanol, or an acid (e.g., acetic acid).
- the extraction buffer is at a concentration between 5 mM to 1 00 mM.
- the drying is freeze-drying.
- the steps of A to C can be repeated prior to step D.
- the extraction buffer in steps A-C is first chloroform/methanol and the extraction buffer is ammonium bicarbonate when steps A-C are repeated.
- the extraction buffer is ammonium bicarbonate in each repetition of steps A-C.
- the foodstuff is digested with a protease, e.g., pepsin, trypsin, chymotrypsin, and/or thermolysin).
- a protease e.g., pepsin, trypsin, chymotrypsin, and/or thermolysin.
- the foodstuff is first digested with pepsin followed by digestion with trypsin.
- the foodstuff is centrifuged to form a supernatant and the supernatant is incubated with the extraction buffer of step A.
- step B is omitted, and the extract, after dialysis, is dried in step C.
- the invention features a method of determining the bioactivity (in a subject having celiac disease) of ATIs in a sample.
- the method includes incubating ATI-reactive cells with an extract suspected of including ATIs and determining an ATI-response in the ATI-reactive cells, thereby determining the bioactivity of the ATIs in a sample.
- the extract suspected of including ATIs is prepared by the method of any one of the embodiments of the first aspect of the invention.
- the ATI-reactive cells express TLR4.
- the ATI-reactive cells are selected from the group consisting of monocytes/macrophages, dendritic cells, or cells transfected with a TLR4-M D2-CD14 oligomeric signaling complex.
- the cells are stable cell lines, e.g., selected from the group consisting of TH P-1 and U937 cells.
- the determination of ATI-response includes quantification of one or more cytokines released by the cells (e.g., IL-8, I L-15, TNFa, CCL2 (MCP-1 ), and CCL5 (RANTES)).
- the quantification can be performed, e.g., by ELISA.
- the cell includes a reporter gene under the control of an ATI-responsive promoter (e.g., the IL-8 promoter) and the determination of an ATI-response includes detection of expression of the reporter gene (e.g., a luminescent or fluorescent protein).
- an ATI-responsive promoter e.g., the IL-8 promoter
- the determination of an ATI-response includes detection of expression of the reporter gene (e.g., a luminescent or fluorescent protein).
- ATI-response can, e.g., include measuring a level of one or more RNAs in the cells associated with an ATI-response (e.g., Hsp27, Hsp70, and/or Hsp90).
- a level of one or more RNAs in the cells associated with an ATI-response e.g., Hsp27, Hsp70, and/or Hsp90.
- the determination of ATI-response includes detecting one or more activation markers on or in the cells (e.g., by flow-cytometry).
- the one or more activation markers is selected from the group consisting of CD80, CD86, M HC class II, IL-12, IL-23, and interferon gamma (intracellular stain).
- the determination of ATI-response includes detecting an alteration is a signaling pathway associated with an ATI response.
- the alteration in a signaling pathway is detected based on the detection of I RF-3, NFkB (p65), or NFkB nuclear translocation.
- the determination of ATI-response includes contacting ovalbumin or glutin specific T cells in the presence of the sample suspected of containing ATIs and measuring the proliferation of the cells.
- the invention features a method of quantifying the amount of ATIs in a foodstuff. The method includes: incubating the foodstuff in an extraction buffer thereby forming an extract; optionally incubating the extract with an alkalating agent; separating the ATIs from the extract; and quantifying the separated ATIs.
- the extraction buffer is a neutral, near neutral, or an alkaline solvent or buffer.
- the extract buffer is selected from the group consisting of PBS, Tris-buffer, water, and ammonium bicarbonate.
- the extract buffer further includes a detergent or detergent mixture.
- the detergent or detergent mixture is selected from the group consisting of sodiumdodecyl sulfate, Triton X-100, Tween-20, and sodium deoxycholate.
- the extraction buffer further includes a reducing agent.
- the reducing agent is selected from the group consisting of mercapto-ethanol or dithioerythritol (DTT).
- the alkylating agent is iodoacetamide and the alkylating agent is further quenched by the addition of access reducing agent.
- the method further includes adding a protease (e.g., trypsin) to the extract.
- a protease e.g., trypsin
- the ATIs can be, e.g., quantified by mass spectrometry, quantitative western blotting, or ELISA.
- the invention features a method of reducing the reactivity of a foodstuff.
- the method includes cultivating a cereal with oxidized glutathione (GSSG) and/or protein bound glutathione (PSSG).
- GSSG oxidized glutathione
- PSSG protein bound glutathione
- the invention features a method of reducing the reactivity of a foodstuff.
- the method includes cultivating a cereal with sulfur rich or sulfur depleted fertilizers.
- the invention features a method of reducing the ATI content of a foodstuff.
- the method includes incubating the foodstuff in an extraction buffer for a duration sufficient to reduce the ATI content of the foodstuff by at least 50% (e.g., by any of the methods described above). This is followed by removal of the extraction buffer.
- the extraction buffer is a neutral, near neutral, or alkaline solvent or buffer.
- the extract buffer is selected from the group consisting of PBS, Tris-buffer, water, and ammonium bicarbonate.
- the extract buffer further includes a detergent or detergent mixture.
- the detergent or detergent mixture is selected from the group consisting of sodiumdodecyl sulfate, Triton X-100, Tween-20, and sodium deoxycholate.
- the extraction buffer can, e.g., further include a reducing agent.
- the reducing agent is selected from the group consisting of mercapto-ethanol, dithioerythritol (DTT), cysteine, or glutathione (GSH) balanced with oxidized glutathione (GSSG).
- the alkylating agent is iodoacetamide and the alkylating agent is further quenched by the addition of access reducing agent.
- the foodstuff is separated mechanically prior to the incubation.
- the mechanically separated foodstuff is dried prior to the incubation (e.g., by air-drying or freeze drying).
- the mechanically separated foodstuff is contacted with an aqueous solvent or an organic solvent having a lower boiling point than water.
- the organic solvent is selected from the group consisting of acetone or ethanol.
- Figure 1 shows the induction of low grade innate inflammation in the intestine of normal mice at 12 hours after oral gavage of 100 ⁇ g of purified wheat ATIs in 200 ⁇ PBS compared to PBS alone or 200 ⁇ g of ATI-containing gliadin (with about 20% of ATIs). Determination of inflammatory genes from the harvested intestine was performed using quantitataive RT-PCR normalized to GAPDH mRNA as housekeeping gene. ATIs caused also a mild upregulation of transglutaminase 2 (TG2) mRNA which is central to celiac disease pathogenesis.
- TG2 transglutaminase 2
- (B): F4-80 positive cells (macrophages, x200) were higher in the group challenged with ATIs or ATI- containing gliadin. Macrophages show a dark colour (peroxidase-staining). Quantitative assessment counting positive cells in 4 high power fields per sample. n 5 per group.
- FIG. 2 shows that an ATI containing diet exacerbates inflammatory bowel disease.
- DSS Dextran sodium sulfate
- FIG. 2 shows that an ATI containing diet exacerbates inflammatory bowel disease.
- DSS Dextran sodium sulfate
- FIG. 3 shows that an ATI containing diet exacerbates experimental multiple sclerosis.
- EAE Experimental autoimmune encephalomyelitis
- E EAE- induction in female C57BL/6 mice on a gluten-free diet (GFD) as in Fig.3A. Animals were divided in four groups: group 1 continued with the GFD (GF to GF), group 2 changed to a diet containing purified ATIs
- Clinical EAE score 0, no disease; 1 , decreased tail tone; 2, abnormal gait (ataxia) and/or impaired righting reflex (hind limb weakness or partial paralysis); 3, partial hind limb paralysis; 4, complete hind limb paralysis; 5, hind limb paralysis with partial fore limp paralysis; 6, moribund or dead.
- FIG. 4 shows that an ATI containing diet exacerbates allergic asthma.
- A-F Murine asthma model induced by ovalbumine (OVA) sensitisations and challenge in female C57BL/6 mice on a gluten-free diet (GFD, casein as protein source) or "normal" chow containing 25% of gluten (with ⁇ 15% w/w as ATIs)/75% casein as protein source). Serum was analysed after the sensitisations (A). Animals were sacrificed after three challenges with PBS or OVA. Bronchoalveolar lavage fluid (BALF) was used to prepare cytospins and count cell populations (B). BALF was also used to measure IL-13 and IL-5 secretion (C and D).
- OVA ovalbumine
- G-l Murine asthma model induced by OVA sensitisations and challenge in female C57BL/6 mice on a gluten-free diet (GFD), as detailed in Fg.4A.
- Figure 5 shows simple method to extract ATIs from wheat (rye, barley) flour, their related products, and from other plant flours for determination of bioactivity.
- Improved buffered solutions contain low- intermediate concentrations of salt (preferably NaCI). Examples are phosphate buffered saline, pH 7.4, or 5-50mM ammonium bicarbonate (Abie). Other concentrations of these chemicals in the solvents or related or unrelated chemicals with buffering properties can be used, such as EDTA, EGTA, other phosphate buffers, etc.
- Dialysis of the extracts can be done against water, Abie solutions or acetic acid (AA). Compared to AA, Abie dialysis yields a higher ATI bioactivity in the cellular readout system.
- Figure 6 shows extraction and bioactivity determination of ATIs from flours and baked foods; complete ATI inactivation by reduction and alkylation at elevated temperature; and ATI content is low or negligible in gluten free foods.
- a and B Total protein extracted sequentially from 1 0g of flour from modern wheat and form more ancient wheat variants (Iran, Kamut) AA: 0.05% acetic acid; Abie, 50 mM ammonium bicarbonate buffer.
- Lipopolysaccharide is used as a positive control.
- Figure 7 shows other high sensitivity bioassays for bioactivity quantification of extracted ATIs.
- ATI extracts with Abie were lyophilized and standardized as to protein content.
- Dose dependent stimulatory response in A) murine bone marrow-derived dendritic cells (BM DCs) and (B) a TLR4/M D-2/CD14/IL-8 Prom/LUCPoterTM HeLa cell line. Compared with the TH P-1 cells used in Fig. 6, these readout cells showed higher sensitivity for ATI-bioactivity (ceiling effect for the luciferase system).
- Figure 8 shows summary ATI bioactivity determinations from flours and baked foods. ATI content is low or negligible in gluten free foods. Classification of grains and food products according to the amount of bioactive ATI (innate stimulating activity as determined by one of the bioassays).
- Figure 9 shows ATIs in extracts from wheat flour on SDS PAGE gels (4-20% gradient).
- A Spring wheat extracted with acetic acid (AA) and subject to salting out using different concentrations of sodium chloride (NaCI).
- ATIs represent most of the band running in the 1 0-15kD range.
- Supernatant (s) and pellet (p) were treated with a without a reducing agent (dithiothreitol, dtt).
- dtt sodium chloride
- ATIs are prominently precipitating between at 0.2 M NaCI, while at 0.5M NaCI gluten will precipitate (bands above the 25kD range).
- B Three different wheat samples extracted with ammonium bicarbonate (Abie) with or without reducing agent. Abie mostly extracts ATIs, with only minor amounts of gluten and other proteins.
- Figure 10 shows determination of total ATI-quantity and ATI-species in different wheat extracts using mass spectrometry and relative amount of main ATIs in different extracts as well as other ATIs that include chymotrypsin inhibitor WCI, endogenous alpha-amylase/subtilisin inhibitor and CMX1 /CMX3.
- Figure 11 shows relative quantity of ATI-species in different wheat extracts using mass spectrometry: (A) Abie extract, (B) chloroform/methanol (CM) extract, (C) commercial extract (1520), and (D) commercial extract(3535). Lyophilized ATI-extracts (Abie and chloroform-methanol) were reduced/alkylated, digested with trypsin and subjected to mass spectrometry.
- Figure 12 shows relative quantity of the major ATI-species CM3 and 0.1 9 in different wheat extracts using mass spectrometry and Western blotting.
- a and B Determination of the percentage of CM3 and 0.1 9 relative to total protein in commercial extract 1520 and 3535 using mass spectrometry.
- C Determination of the percentage of CM3 and 0.1 9 relative to total protein in commercial extract 1520 and 3535 using mass spectrometry.
- Figure 13 shows ATI bioactivity of fermented wheat dough.
- A ATI bioactivity in 90% wheat dough fermented with 1 0% rye malt. Samples were extracted with Abie, lyophilized and reconstituted.
- IL-8 IL-8, MCP-1 and TNF-a measured by ELISA. Bars in represent samples fermented with different strains (Lactobacillus sanfranciscensis (mutant), L. Sakei, L. Reuteri and L. Sanfranciscensis). Other bars represent a control sample of unfermented rye malt. Results are from 3-5 samples, and analysed for sugnificance using one way ANOVA and compared against the unfermented sample (control) using Dunnett's test. Level of significance (p ⁇ 0.05) was represented by asterisks. * p ⁇ 0.05, ** p ⁇ 0.01 ,
- FIG. 13A ATI bioactivity of fermented dough prepared with 1 00% whole wheat. Samples were extracted with Abie and analyzed as described above (Fig.13A).
- Figure 14 shows inhibition of ATI-bioactivity using the natural TLR4-antagonist LPS-RS. TLR4-inhibitory lipopolysaccharide from Rhodobacter sphaeroides (LPS-RS, 1 .5 ⁇ g/ml_ ) was pre-incubated with THP-1 cells for 30 min, then ATIs enriched in CM3 and 0.1 9 (37 ⁇ g/ml_) were added and cultured overnight.
- LPS-RS Rhodobacter sphaeroides
- E.coli LPS (12.5ng/mL) was also cultured overnight with THP-1 cells pre incubated (30 min) with LPS-RS (250ng/mL).
- ATIs Amylase trypsin inhibitors
- ATIs Amylase trypsin inhibitors
- ATIs as nutritional activators of TLR4 is different from that of gluten in celiac disease and of wheat (rye, barley) proteins in allergy.
- ATIs can also act as inhalative allergens (Schuppan et al, Gastroenterology 2009; Batais et al, Eur Ann Allergy Clinic 2008; Catassi et al, Nutrients 2013; Uvackova et al, J Proteome Res 2013).
- the disease causing potency of ATIs ingested with wheat, barley, or rye is not limited to the gastrointestinal tract, but is also likely implicated to affect other extraintestinal diseases (Tilg et al, Gastroenterology 201 3).
- ATIs induce low grade but significant inflammation in the small intestine and colon.
- nutritional ATIs exacerbate inflammatory diseases in general, as shown in mouse models of inflammatory bowel disease, of multiple sclerosis, and of allergic asthma.
- Figures 1 -4 demonstrate this "adjuvant effect" in the mentioned in vivo situations and diseases.
- the methods of the invention can be performed in a variety of foodstuffs suspected of containing ATIs, including any food stuff having a cereal grain component (e.g., baked goods as described herein).
- Example 1 Methods to determine the (proinflammatory) bioactivity due to ATIs in unprocessed and processed foods
- Buffer/solvent extractive method (applicable to most unprocessed foods, see sketch in Fig.5):
- Freeze dried material is reconstituted in e.g. 2 ml of PBS or cell culture compatible buffer or media
- CM chloroform/methanol
- Buffers may vary in composition. Thus ammonium bicarbonate can also may be used in lower (e.g., 5 mM) or higher (e.g., 1 00 mM) concentrations, other neutral or slightly alkaline buffers can be used. Even acidic extraction is possible, e.g., by using 50 mM acetic acid. However acidic buffers co- extract significant amounts of other proteins such as gluten (further described in detail below).
- Quantitative ATI extraction from further processed e.g. cooked or baked foods such as bread, cookies, pasta or pizza
- Steps 2.-3 can also be omitted, without significant loss of bioactivity
- Pellet is digested with (gastrointestinal) proteases that do not significantly degrade the highly disulfide linked ATIs, such as pepsin followed by trypsin to better extract ATIs from the food matrix.
- proteases that do not significantly degrade the highly disulfide linked ATIs, such as pepsin followed by trypsin to better extract ATIs from the food matrix.
- proteolytic digestion pepsin-trypsin digestion protocol
- Precipitate is removed by centrifugation at 4,500 rpm for 1 0 min.
- Protein concentration may be determined by using a bicinchoninic acid protein assay (Pierce).
- Freeze dried material is reconstituted in e.g. 2 ml of PBS or cell culture compatible buffer or media.
- buffers and buffer and enzyme concentrations can be used, as long as enzyme activity is maintained. I n some, e.g., hardly baked, foods, more harsh conditions may be applicable. Also other enzymes such as chymotrypsin or thermolysin can be used exclusively (as neutral protease) or in combination with trypsin, since these can leave ATIs largely intact, while degrading other, major (cereal) proteins such as gluten (Camus and Laporte, Reprod Nutr Dev 1 980; Gessendorfer et al, Anal Bioanal Chem 2009; Jos et al, Scand J Gastroenterol 1975; Rombouts et al, Sci Rep 2013).
- ATIs Due to their resistance to gastrointestinal proteases, ATIs remain largely intact after these proteolytic extraction procedures and maintain bioactivity. Our in vitro studies show that even with purified ATIs, the above-described digestion procedure reduces bioactivity by maximally 40%. Moreover, extracted bioactivity of 1 g of wheat flour before baking (10-20 min at 150-1 80 S C) is reduced by maximally 50% post baking.
- ATI extracts (freeze dried or centrifuged/concentrated) as described in Example 1 and reconstituted in cell-culture compatible buffers, are added to cultures of ATI-reactive (TLR4-bearing) cells, preferably monocytes/macrophages, dendritic cells, or cells transfected with the TLR4-M D2-CD14 oligomeric signaling complex. It is also preferable to use stable cell lines such as human TH P-1 , U937, or TLR4-M D2-CD14 transfected H EK-293 cells (obtainable e.g. from American Type Culture Collection). Apart from human cells, cells of other species such as mouse or rat can be used.
- Culture is preferably in complete RPMI or DMEM supplemented with 1 00 l U/ml penicillin/100 g/ml streptomycin and 10% fetal calf serum at 37 ⁇ in a 5% C02 atmosphere. Cells should be mycoplasma-free for reproducible results. Usually 1 -1 00 ⁇ _ of the reconstituted extracts described in Example 1 are added to the cultures of the indicator cells (preferably seeded at densities of 25,000-200,000 cells in 0.2-1 ml_ medium in 24 well culture plates). Culture supernatants and/or cells are preferably harvested at 12-24 h post addition of the extracts to be tested.
- chemokines and/or cytokines into the cell culture media due to addition of ATIs/ ATI extracts to the above cells can be quantified to serve as a quantitative measure of stimulatory ATI activity.
- chemokines and/or cytokines into the cell culture media due to addition of ATIs/ ATI extracts to the above cells can be quantified to serve as a quantitative measure of stimulatory ATI activity.
- Examples are IL-8, IL-15, TNFa, CCL2 (MCP-1 ), CCL5 (RANTES). This can be done using commercial validated ELISAs (e.g. IL-8 and TNFa [BD]; MCP-1 , IL-15, RANTES [R&D Systems]) according to the manufacturers' protocols.
- TLR4-dependent cytokines and chemokines Apart from TLR4-dependent cytokines and chemokines, other secreted or cell extractable proteins/peptides downstream of TLR4 activation can be measured, including heat shock proteins (such as Hsp27, Hsp70, Hsp90) activation or known from the literature.
- heat shock proteins such as Hsp27, Hsp70, Hsp90 activation or known from the literature.
- LPS lipopolysaccharide
- RNA is isolated from cells using e.g. TRIzol (I nvitrogen). Quantitative RT-PCR is preferably performed using exon-exon boundary-spanning primer sequences and e.g., the SYBR green or Taqman methodology as described for a set of cytokines by Junker et al (2012). Apart from TLR4-dependent cytokines and chemokines, other transcripts downstream of TLR4 activation can be measured, including heat shock proteins (such as Hsp27, Hsp70, Hsp90) but also other transcriptionally activated genes known from the literature.
- heat shock proteins such as Hsp27, Hsp70, Hsp90
- Activation markers are e.g. CD80, CD86, MHC class I I, IL-12, IL-23, interferon gamma (intracellular stain) and many others known from the common literature.
- Cells are preincubated with FcR blocking reagent (Miltenyi Biotec) for 15 min at 4 °C before staining preferably with fluorescent-labeled monoclonal antibodies to these activation markers at predetermined concentrations for e.g. 30 min at 4 ⁇ . Cells are then washed with staining buffer (e.g.
- ATI activity is based on activation (or inhibition) of signaling pathways in the responsive cells. Examples are the phosphorylation of certain kinase substrates, such as I RF-3 or NFkB (p65), or N FkB nuclear translocation.
- TLR4-complex stimulated antigen presenting cells such as monocytes, macrophages, dendritic or B cells
- TLR4-complex stimulated antigen presenting cells such as monocytes, macrophages, dendritic or B cells
- An example is the incubation of ovalbumin or gluten specific T cell lines or T cell clones, and HLA-compatible antigen presenting cells or cell lines loaded with ovalbumin (ova peptide) or gluten (gluten peptide), respectively.
- An (unknown amount of) ATI added to these cultures will dose-dependently stimulate T cell proliferation which can be measured in standard T cell proliferation assays, using e.g. 3H-thymidine or BrdU incorporation.
- a simplified version of such assay is the addition of ATI-containing solutions to a classical mixed lymphocyter reaction with white blood cells of peripheral human or non-human, e.g. rodent, blood, or e.g., rodent splenocytes.
- Example 2 Methods to determine the chemical quantity of ATIs in unprocessed and processed foods.
- the other major gluten containing cereals (barley and rye) express various amylase/trypsin/chymotrypsin/subtilisin inhibitors with high sequence homology to the wheat ATIs
- One gram of the (dried) food to be analyzed is extracted in neutral, near neutral or alkaline solvents/buffers, such as PBS, Tris-buffer, ammonium bicarbonate, preferably containing a detergent or detergent mixture (e.g., sodiumdodecyl sulfate, Triton X-100, Tween-20, sodium deoxycholate), and a reducing agent, such as 2-mercapto-ethanol, dithioerythritol (DTT), e.g. at 5-200 mM and at 37 ⁇ for 30 min to 4 hrs.
- a detergent or detergent mixture e.g., sodiumdodecyl sulfate, Triton X-100, Tween-20, sodium deoxycholate
- a reducing agent such as 2-mercapto-ethanol, dithioerythritol (DTT), e.g. at 5-200 mM and at 37 ⁇ for 30 min to 4 hrs.
- samples should be alkylated, e.g., with iodoacetamide at a final concentration of 20-500 mM for 1 0-60 min in the dark. Iodoacetamide will be quenched by excess reducing agents, e.g., 200 mM DTT.
- the cleared supernatant can be separated from small molecular weight contaminants e.g. by dialysis or ultrafiltration. For mass spectrometry the suspension (cleared supernatant) can be further digested, e.g., with trypsin.
- samples can be freeze-dried, concentrated in solution, e.g., by
- High titer antibodies have been produced against a mixture of ATIs extracted from hexaploid wheat and against several antigenic epitopes of major ATIs such as CM3, CM 16, 0.19 or 0.54. Examples of Western blot characterization are shown in Figs.12C.
- ATI species Up to 16 ATI species have been described in what based on genetic analysis. However, a subset of ATIs usually represent >90% of all ATIs. These are noncovalently linked tetrameric CM2, CM3, CM1 6, dimeric 0.1 9, 0.54, and monomers of e.g. 0.1 9 and 0.54 (Altenbach et al, BMC Res Notes 201 1 ; Dupont et al, Proteome Sci 201 1 ). Our data indicate that TLR4-stimulatory ability as highest for di- and tetrameric ATIs and lowest for monomeric ATIs . Quantification of the major 3-8 ATI species in a given wheat, rye, or barley variant will approximate total ATI quantification. If desired, also the minor species can be quantified.
- ATIs ATIs
- a detection system such as biotin, alkaline phosphatase, peroxidase, fluorescent, or luminescent indicators, and state-of the art detection systems.
- This also includes assays based on inhibition which require, e.g., a coated antibody and a labeled ATI standard to compete with ATIs in the unknown sample.
- Other state of the art assays such as radioimmunoassays (equilibrium or inhibition format) or bead assays can also be used, including quantification by multiplexed assays.
- Example 3 Methods to prevent correct intramolecular disulfide formation in ATIs during grain growth or filling
- GSSG oxidized glutathione
- PSSG protein bound glutathione
- Methods to promote the formation of PSSG bonds are cultivation with excess GSH or GSSG, the cultivation with or induction of enzymes that decrease the plant's redox potential such as superoxide dismutase or catalase activities.
- An alternative strategy is modulation of sulphur supply to the growing wheat (rye, barley), e.g., via use of sulphur rich vs. sulphur depleted fertilizers, also in sequence.
- resultant flour proteins including ATIs are more fixed in their disulfide structures and less susceptible to proteolytic degradation by external proteases or proteases if the gastrointestinal tract (Reinbold et al, J Agricult Food Chem 2008), although ATI content is (slightly) decreased.
- Example 4 Methods to remove ATIs or abolish ATI bioactivity from complex foods by thorough extraction from, e.g., wheat (rye, barley, or by fermentation and their ancestral grains) prior to introduction into the food chain
- ATIs are quite resistant to degradation by many known proteases, including digestive enzymes of the human gastrointestinal tract such as pepsin, trypsin and chymotrypsin. Much of this resistance is due to the presence of several, usually five, intramolecular disulfide bonds that generate a compact secondary structure which is usually composed of four major alpha helices which are arranged up-and-down, securing a compact structure and hydrophobic interaction surfaces for di- and tetramerization (Oda et al, Biochemistry 1997).
- Useful methods to significantly decrease (>70%, preferably 80% and more) bioactive ATIs in e.g., flours are therefore based on 1 ) exhaustive extraction using preferably water based buffers, and 2) disulfide reduction which facilitates unfolding, eliminate bioactivity (i.e., activation of the TLR4-complex) and permit proteolytic digestion either before or during ingestion of the thus prepared foods.
- Proteolytic digestion of the reduced and unfolded ATIs can be achieved easily with common proteases used in the food industry, including e.g. , pepsin at acidic pH, or e.g. trypsin, chymotrypsin or subtilisin at near neutral or alkaline pH.
- Enzymes that degrade unfolded or denatured ATIs are also produced during certain fermentation processes, as described below, including sourdough fermentation or reductive fermentation. This also includes fermentations that produce specific enzyme activities to cleave (unfolded, denatured) ATIs, including bacteria that have been engineered to produce such activity for the food industry.
- ATIs can be extracted from flours and even processed foods using the methods described above
- the extracted flour (food) can be separated mechanically, e.g., by sedimentation or centrifugation, and then freeze-dried or (preferably) dried in air or other (inert) gases that permit drying of bulk quantities. Before drying the pellet, other steps, such as washes with water and/or with (organic) solvents that have a lower boiling point than water but bind residual water, such as acetone, ethanol, or similar solvents used in the food industry can be used for removal of traces of salt or acid (from the extraction buffer), and residual water. Residual water can also be retained when the extracted flour is frozen for storage and transport, or directly used for further food processing, such as fermentation or dough preparation.
- 100 g of the (dried) flour or food is incubated in neutral, near neutral, or alkaline solvents/buffers, such as water or saline with pH adjustment, or with PBS and a reducing agent, such as cysteine, or glutathione (GSH) balanced with oxidized glutathione (GSSG), at temperatures that can range between 4°C and 1 00 °C, for times that can range between one second and 24 hrs.
- a reducing agent such as cysteine, or glutathione (GSH) balanced with oxidized glutathione (GSSG)
- GSH glutathione
- GSSG oxidized glutathione
- Other usually mildly reducing agents that are known in the food industry can also be used.
- Reduced ATIs are preferably denatured at temperatures above 50 °C and can be locked in this denatured state by disulfide linkage with, e.g., cysteine or GSH, or via mis-folded, newly generated, intra- and intermolecular disulfide bonds.
- disulfide linkage e.g., cysteine or GSH
- Other free SH-group blocking agents used in the food industry can also be employed.
- Fixation of partly reduced and thus severed intramolecular disulfides in ATIs can also be brought about during dough mixing by the addition of vitamin C or other pro-oxidative systems that generate, e.g., activated oxygen. This has been demonstrated for disulfides in glutenins (Koehler P et al, J Agricult Food Chem 2003a and b), but is also effective in ATIs.
- Fermentation of wheat (rye, barley) dough with lactobacilli is used to enhance the degradation of gluten proteins under acidic conditions.
- Select lactobacilli that have an active thiol (disulfide reducing) metabolism are particularly suited to reduce and subsequently degrade ATIs proteolytically.
- An example are Lactobacillus reuteri and L. sanfranciscensis which efficiently deactivate proteins such as the highly disulfide linked ovotransferrin of wheat as well as ATIs.
- Proteolytic activity is mainly brought about by wheat aspartic acid proteases (Loponen et al, J Ag ricult Food Chem 2007; Loponen et al, J Agricult Food Chem 2008), but other proteolytic enzymes used in the food industry can be added. Fermentation of wheat flour and other ATI-containing flours can be done e.g. with varying proportions of rye malt in the dough, such as 5-20%. Here, apart from adding beneficial bacteria that are used in the food industry to prepare e.g.
- sourdough (Lactobacillus species), rye malt serves as source of proteolytic enzymes that were shown to degrade immunogenic gluten proteins (Loponen et al, J Agricult Food Chem 2007).
- This method can be combined with any of the other ATI-reducing methods described herein. Reduction of ATI content by non-reductive and reductive fermentation of ATI-containing flours and doughs
- the doughs can be prepared with whole wheat flour and without additives. Optimization is possible using refined instead of crude flours, or addition of common agents that are used in the food industry to improve fermentation or dough quality.
- An example is the addition of reducing agents, such as cysteine or glutathione, either before, during or after fermentation.
- Another alternative is the use of fermenting bacteria with high disulfide reducing ability.
- Such strains have been described and comprise, e.g., Lactobacillus sanfranciscensis and L. reuteri LTH2584.
- Fig.13 shows the results of fermentation experiments (24 hrs) performed. ATI activity was determined in two sequential combined ammonium bicarbonate extractions from the fermented and then frozen doughs, using the methodology described above.
- Lactobacillus sanfranciscensis (high SH-levels in dough and reduction of disulfide bonds in proteins owing to glutahione reductase activity);
- Lactobacillus sanfranciscensis delta gsrH (low SH-levels in dough as gene coding for glutathione reductase gene was disrupted) ;
- Lactobacillus reuteri LTH2584 (high SH-levels owing to cystathionine gamma lyase);
- Controls for appropriate fermentation Doughs were analysed with respect to pH, organic acid levels and SH-groups, as were the numbers of fermenting bacteria. The data demonstrate an up to -50- 60% reduction in ATI-bioactivity in the sourdoughs that were fermented with Lactobacilli in general, either with or without rye malt addition. This indicates significant proteolytic digestion and thus inactivation of ATIs by fermentation in general, without higher degradation activity by disulfide reducing strains.
- thiol-reducing bacteria L. sanfranciscensis and L. reuteri
- post fermentation heating of the dough to elevated temperatures that do not yet inactivate the rye (barley) malt or Lactobacillus-derived proteolytic enzymes could further reduce ATI bioactivity down to 20% in the doughs subject to thiol reducing Lactobacilli vs. 30% in the non-thiol-reducing bacteria, indicating an advantage of the former strains.
- reductive fermentation more than conventional fermentation leads to disulfide reduction of ATIs which then become susceptible to proteolytic degradation by enzymes used in the food industry, such as those produced by Lactobacillae or that are present in malt.
- Example 5 TLR4 antagonistic compounds that can be added to ATI containing foods
- TLR4 antagonists There are several (weak to moderately active) oral TLR4 antagonists, many of them of herbal origin, with long-term use as spices or food additives. These are e.g. alkaloids, aromatic compounds, polyphenols, peptides or proteins (Rossignal and Lynn 2005; Lucas and Maes, Mol Neurobiol 2013).
- Examples include, but are not limited to, Bartonella quintana lipopolysaccharide (Popa et al, Infect Immunol 2007); extracts of leaves from Clerodendrum (Kouakou et al, BMC Complement Altern Med 2013); cinnamon extract and its active components (Kanuri et al, J Nutr 2009); eritoran mimicking the MD component of the TLR4-M D2-CD14 complex, formulated to be resistant to gastric or intestinal hydrolysis (Shirey et al, Nature 2013); epigallocatechin-3-gallate from, e.g., green tea (Hong et al, J Immunol 201 0; Bao et al, Mol Nutr Food Res 2013) ; 6-shogaol and 1 -dehydro-1 0-gingerdione (1 D1 0G) from Ginger (Ahn et al, Mol Cless 2009; Park et al, Biochem Biophys Res Communic 2012); Melatonin
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Microbiology (AREA)
- Peptides Or Proteins (AREA)
Abstract
The present invention features methods of extracting amylase trypsin inhibitors (ATIs) from processed and unprocessed foodstuff, determining bioactivity of ATIs, qualifying the amount of ATIs in a foodstuff, and reducing the content of ATIs in a foodstuff.
Description
METHODS FOR DETERMINATION OF BIOACTIVITY, REMOVAL, OR INACTIVATION CEREAL AMYLASE TRYPSIN INHIBITORS IN CEREALS, FLOURS AND COMPLEX FOODS
BACKGROUND
Ingestion of wheat, barley, or rye triggers small intestinal inflammation in patients with celiac disease. Specifically, the storage proteins of these cereals (gluten) elicit an adaptive Th1 -mediated immune response in individuals carrying HLA-DQ2 or HLA-DQ8 as a major genetic predisposition. This well-defined role of adaptive immunity contrasts with an ill defined component of innate immunity in celiac disease. We have identified the alpha-amylase/trypsin inhibitors (ATIs) CM3 and 0.19, pest resistance molecules in wheat, as strong activators of innate immune responses in monocytes, macrophages, and dendritic cells. ATIs engage the TLR4-M D2-CD14 complex and lead to up-regulation of maturation markers. ATIs then elicit release of proinflammatory cytokines from cells inceliac and non-celiac patients. Mice deficient in TLR4 or TLR4 signaling are protected from intestinal and systemic immune responses upon oral challenge with ATIs. These findings define cereal ATIs as contributors to celiac disease. Moreover, ATIs may fuel inflammation and immune reactions in other intestinal and non-intestinal immune disorders. There exists a need for novel technologies and methods that are able to remove ATI from foods.
SUMMARY OF THE INVENTION
The present invention features methods of extracting ATIs from processed and unprocessed foodstuff, determining bioactivity of ATIs, qualifying the amount of ATIs in a foodstuff, and reducing the content of ATIs in a foodstuff.
In a first aspect, the invention features a method of extracting amylase trypsin inhibitors (ATIs) from a foodstuff. The method includes the steps of A) incubating the foodstuff with an extraction buffer in a mixture, B) centrifuging the mixture to form a pellet and supernatant, C) drying the supernatant, and D) reconstituting the dried supernatant in a reconstitution buffer. The extracted ATIs are present in the reconstitution buffer.
In one embodiment, the foodstuff is unprocessed prior to extraction.
In another embodiment, the foodstuff is a processed foodstuff.
In one embodiment, prior to incubating the foodstuff with an extraction buffer in a mixture, the foodstuff is ground.
In one embodiment, prior to incubating the foodstuff with an extraction buffer in a mixture, the foodstuff is defatted. Particularly, the defatting is performed by the incubation of the foodstuff with methanol/diethylether (e.g., at a 1 :1 ratio).
In one embodiment, the extraction buffer is ammonium bicarbonate, chloroform/methanol, or an acid (e.g., acetic acid).
In one embodiment, the extraction buffer is at a concentration between 5 mM to 1 00 mM.
In one embodiment, the drying is freeze-drying.
In all of the aforementioned embodiments of the first aspect of the invention, the steps of A to C can be repeated prior to step D.
In one embodiment, the extraction buffer in steps A-C is first chloroform/methanol and the extraction buffer is ammonium bicarbonate when steps A-C are repeated. In another embodiment, the extraction buffer is ammonium bicarbonate in each repetition of steps A-C.
In one embodiment, prior to step A, the foodstuff is digested with a protease, e.g., pepsin, trypsin, chymotrypsin, and/or thermolysin).
In one embodiment, the foodstuff is first digested with pepsin followed by digestion with trypsin.
In one embodiment, after the foodstuff is digested with a protease, the foodstuff is centrifuged to form a supernatant and the supernatant is incubated with the extraction buffer of step A. Particularly, where the incubation is performed as a dialysis incubation, step B is omitted, and the extract, after dialysis, is dried in step C.
In a second aspect, the invention features a method of determining the bioactivity (in a subject having celiac disease) of ATIs in a sample. The method includes incubating ATI-reactive cells with an extract suspected of including ATIs and determining an ATI-response in the ATI-reactive cells, thereby determining the bioactivity of the ATIs in a sample.
In one embodiment, the extract suspected of including ATIs is prepared by the method of any one of the embodiments of the first aspect of the invention.
In one embodiment, the ATI-reactive cells express TLR4. Particularly, the ATI-reactive cells are selected from the group consisting of monocytes/macrophages, dendritic cells, or cells transfected with a TLR4-M D2-CD14 oligomeric signaling complex. Particularly, the cells are stable cell lines, e.g., selected from the group consisting of TH P-1 and U937 cells.
In one embodiment, the determination of ATI-response includes quantification of one or more cytokines released by the cells (e.g., IL-8, I L-15, TNFa, CCL2 (MCP-1 ), and CCL5 (RANTES)). The quantification can be performed, e.g., by ELISA.
In all of the aforementioned embodiments of the second aspect of the invention, the cell includes a reporter gene under the control of an ATI-responsive promoter (e.g., the IL-8 promoter) and the determination of an ATI-response includes detection of expression of the reporter gene (e.g., a luminescent or fluorescent protein).
In all of the aforementioned embodiments of the second aspect of the invention, the
determination of ATI-response can, e.g., include measuring a level of one or more RNAs in the cells associated with an ATI-response (e.g., Hsp27, Hsp70, and/or Hsp90).
In one embodiment, the determination of ATI-response includes detecting one or more activation markers on or in the cells (e.g., by flow-cytometry). Particularly, the one or more activation markers is selected from the group consisting of CD80, CD86, M HC class II, IL-12, IL-23, and interferon gamma (intracellular stain).
In one embodiment, the determination of ATI-response includes detecting an alteration is a signaling pathway associated with an ATI response. Particularly, the alteration in a signaling pathway is detected based on the detection of I RF-3, NFkB (p65), or NFkB nuclear translocation.
In one embodiment, the determination of ATI-response includes contacting ovalbumin or glutin specific T cells in the presence of the sample suspected of containing ATIs and measuring the proliferation of the cells.
In a third aspect of the invention, the invention features a method of quantifying the amount of ATIs in a foodstuff. The method includes: incubating the foodstuff in an extraction buffer thereby forming an extract; optionally incubating the extract with an alkalating agent; separating the ATIs from the extract; and quantifying the separated ATIs.
In one embodiment, the extraction buffer is a neutral, near neutral, or an alkaline solvent or buffer. Particularly, the extract buffer is selected from the group consisting of PBS, Tris-buffer, water, and ammonium bicarbonate.
In one embodiment, the extract buffer further includes a detergent or detergent mixture.
Particularly, the detergent or detergent mixture is selected from the group consisting of sodiumdodecyl sulfate, Triton X-100, Tween-20, and sodium deoxycholate.
In one embodiment, the extraction buffer further includes a reducing agent. Particularly, the reducing agent is selected from the group consisting of mercapto-ethanol or dithioerythritol (DTT).
In one embodiment, the alkylating agent is iodoacetamide and the alkylating agent is further quenched by the addition of access reducing agent.
In one embodiment, the method further includes adding a protease (e.g., trypsin) to the extract.
In all of the aforementioned embodiments of the third aspect of the invention, the ATIs can be, e.g., quantified by mass spectrometry, quantitative western blotting, or ELISA.
In a fourth aspect of the invention, the invention features a method of reducing the reactivity of a foodstuff. The method includes cultivating a cereal with oxidized glutathione (GSSG) and/or protein bound glutathione (PSSG).
In a fifth aspect of the invention, the invention features a method of reducing the reactivity of a foodstuff. The method includes cultivating a cereal with sulfur rich or sulfur depleted fertilizers.
In a sixth aspect of the invention, the invention features a method of reducing the ATI content of a foodstuff. The method includes incubating the foodstuff in an extraction buffer for a duration sufficient to reduce the ATI content of the foodstuff by at least 50% (e.g., by any of the methods described above). This is followed by removal of the extraction buffer.
In one embodiment, the extraction buffer is a neutral, near neutral, or alkaline solvent or buffer. Particularly, the extract buffer is selected from the group consisting of PBS, Tris-buffer, water, and ammonium bicarbonate.
In one embodiment, the extract buffer further includes a detergent or detergent mixture.
Particularly, the detergent or detergent mixture is selected from the group consisting of sodiumdodecyl sulfate, Triton X-100, Tween-20, and sodium deoxycholate.
In all of the aforementioned embodiments of the sixth aspect of the invention, the extraction buffer can, e.g., further include a reducing agent. Particularly, the reducing agent is selected from the group consisting of mercapto-ethanol, dithioerythritol (DTT), cysteine, or glutathione (GSH) balanced with oxidized glutathione (GSSG).
In one embodiment, the alkylating agent is iodoacetamide and the alkylating agent is further quenched by the addition of access reducing agent.
In all of the aforementioned embodiments of the sixth aspect of the invention, the foodstuff is separated mechanically prior to the incubation. Particularly, the mechanically separated foodstuff is dried prior to the incubation (e.g., by air-drying or freeze drying).
In one embodiment, prior to the drying, the mechanically separated foodstuff is contacted with an aqueous solvent or an organic solvent having a lower boiling point than water. Particularly, the organic solvent is selected from the group consisting of acetone or ethanol. DESCRIPTION OF THE DRAWINGS
Figure 1 shows the induction of low grade innate inflammation in the intestine of normal mice at 12 hours after oral gavage of 100 μg of purified wheat ATIs in 200 μΙ PBS compared to PBS alone or 200 μg of ATI-containing gliadin (with about 20% of ATIs). Determination of inflammatory genes from the harvested intestine was performed using quantitataive RT-PCR normalized to GAPDH mRNA as housekeeping gene. ATIs caused also a mild upregulation of transglutaminase 2 (TG2) mRNA which is central to celiac disease pathogenesis. (A): Transcript levels of inflammatory markers (MCP-1 =CCL2 and KC=IL-8) and of TG2 in the intestine were up-regulated after feeding a single dose of ATIs or ATI-containing gliadin (commercial product from Sigma) to C57BL/6 mice kept on a gluten-free diet. n=5 per group; *p<0.05. (B): F4-80 positive cells (macrophages, x200) were higher in the group challenged with ATIs or ATI- containing gliadin. Macrophages show a dark colour (peroxidase-staining). Quantitative assessment counting positive cells in 4 high power fields per sample. n=5 per group.
Figure 2 shows that an ATI containing diet exacerbates inflammatory bowel disease. Dextran sodium sulfate (DSS) colitis (Lauroui et al., PLoS One 7:e32084, 2012; Wirtz et al. Nat. Protoc. 2:541 -546, 2007) was induced by adding a low dose of 1 .5% DSS (w/v) in the drinking water of female C57BL/6 mice on a gluten-free diet (GFD, purely casein-based protein source) or "normal" chow containing 25% of gluten (with ~15% w/w as ATIs)/75% casein as protein source. Mouse body weight changes that are strong indicators of the severity of colitis were recorded every two days (data by Dr. G. Pickert in the Ps group). Changes were significant from day 12 on (p<0.05 ATI-free vs. ATI-containing chow).
Figure 3 shows that an ATI containing diet exacerbates experimental multiple sclerosis. (A-D):
Experimental autoimmune encephalomyelitis (EAE), a suitable model of multiple sclerosis, was induced by immunization with myelin oligodendrocyte protein (MOG peptide emulsified in complete Freund's adjuvant and pertussis toxin on the first day of immunization and 2 days later) in female C57BL/6 mice on a gluten-free diet (GFD, casein as protein source). Animals were divided in group 1 continuing on the
GFD and group 2 changing to a diet containing 25% of gluten (with ~15% w/w as ATIs)/75% casein as protein source). CNS-infiltrating total T cell (A), CD4+ (B) and CD8+ (C) T cell numbers were calculated using FACS-analysis of extracted brain tissue (shown is a representative experiment of three independent experiments with n=4 mice per group). Mice were observed and scored daily for clinical signs of EAE after induction (days post induction, DPI) (D). Data are representative of three independent experiments (n=1 0 per group, maximal clinical score 3.75). *p<0.05 comparing both groups. (E): EAE- induction in female C57BL/6 mice on a gluten-free diet (GFD) as in Fig.3A. Animals were divided in four groups: group 1 continued with the GFD (GF to GF), group 2 changed to a diet containing purified ATIs
(GF to ATI ; casein-based protein source with 1 % purified ATIs), group 3 changed to a diet containing
25% gluten (~15% w/w as ATIs) (GF to G), and group 4 changed to a diet containing 25% gluten with partial de-enrichment ATIs by extraction (reduction of ATI-content by ~70% (GF to G-ATI). Mice were observed and scored daily for clinical signs of EAE after induction (days post induction, DPI) (D). Data
represents one independent experiment (n=1 0 per group, maximal clinical score: 2.5: incipient hindleg paralysis, see below). *p<0.05 for the area under curve from baseline to peak of disease for GF/GF vs GF/ATI. Clinical EAE score: 0, no disease; 1 , decreased tail tone; 2, abnormal gait (ataxia) and/or impaired righting reflex (hind limb weakness or partial paralysis); 3, partial hind limb paralysis; 4, complete hind limb paralysis; 5, hind limb paralysis with partial fore limp paralysis; 6, moribund or dead.
Figure 4 shows that an ATI containing diet exacerbates allergic asthma. (A-F): Murine asthma model induced by ovalbumine (OVA) sensitisations and challenge in female C57BL/6 mice on a gluten-free diet (GFD, casein as protein source) or "normal" chow containing 25% of gluten (with ~15% w/w as ATIs)/75% casein as protein source). Serum was analysed after the sensitisations (A). Animals were sacrificed after three challenges with PBS or OVA. Bronchoalveolar lavage fluid (BALF) was used to prepare cytospins and count cell populations (B). BALF was also used to measure IL-13 and IL-5 secretion (C and D). Histological lung sections were scored after H&E and PAS staining (E and F). (G-l): Murine asthma model induced by OVA sensitisations and challenge in female C57BL/6 mice on a gluten-free diet (GFD), as detailed in Fg.4A. Animals were divided in 5 groups: group 1 continued with the GFD and was sensitised with PBS, group 2 continued with the GFD and was sensitised with OVA, group 3 changed to a diet containing 25% gluten (with ~15% w/w as ATIs)/75% casein as protein source), group 4 changed to a diet containing ATIs (casein-based protein source with 1 % purified ATIs), and group 5 changed to a diet containing 25% gluten with low levels of ATIs (de-enriched of ATIs by ~70%). All groups were challenged with OVA and then sacrificed. Splenocytes were isolated from each group and stimulated with 3 μg/mL of OVA for proliferation assays (A). Supernatants were analysed for cytokines IL-13 and I L-5 (B and C). **p<0.01 , ***p<0.005.
Figure 5 shows simple method to extract ATIs from wheat (rye, barley) flour, their related products, and from other plant flours for determination of bioactivity. Improved buffered solutions contain low- intermediate concentrations of salt (preferably NaCI). Examples are phosphate buffered saline, pH 7.4, or 5-50mM ammonium bicarbonate (Abie). Other concentrations of these chemicals in the solvents or related or unrelated chemicals with buffering properties can be used, such as EDTA, EGTA, other phosphate buffers, etc. Dialysis of the extracts can be done against water, Abie solutions or acetic acid (AA). Compared to AA, Abie dialysis yields a higher ATI bioactivity in the cellular readout system.
Figure 6 shows extraction and bioactivity determination of ATIs from flours and baked foods; complete ATI inactivation by reduction and alkylation at elevated temperature; and ATI content is low or negligible in gluten free foods. (A and B) Total protein extracted sequentially from 1 0g of flour from modern wheat and form more ancient wheat variants (Iran, Kamut) AA: 0.05% acetic acid; Abie, 50 mM ammonium bicarbonate buffer. Bioactivity assay using the human monocyte-macrophage cell line THP-1 and standardized lyophoilized extracts (combined 1 st and 2nd extract representing >90% of total ATIs). (C, D, and E) Cytokine release (IL-8 and TNF-a) after stimulation of TH P-1 cells with normalized ATI-extracts from different grains and products. Dried white bread and pasta were pulverized and extracted using pepsin and trypsin containing buffers. The dialysed and lyophilised extracts were standardized and used in the bioassay. Notably, there is no significant loss of bioactivity after baking or boiling (D). (F)
Reduction/alkylation (R/A) with dithiothreitol/iodoacetamide at 50°C on enriched ATIs from spring wheat indicates complete reductive inactivation of ATI bioactivity. Lipopolysaccharide (LPS) is used as a positive control. Figure 7 shows other high sensitivity bioassays for bioactivity quantification of extracted ATIs. ATI extracts with Abie were lyophilized and standardized as to protein content. Dose dependent stimulatory response in (A) murine bone marrow-derived dendritic cells (BM DCs) and (B) a TLR4/M D-2/CD14/IL-8 Prom/LUCPoter™ HeLa cell line. Compared with the TH P-1 cells used in Fig. 6, these readout cells showed higher sensitivity for ATI-bioactivity (ceiling effect for the luciferase system). Figure 8 shows summary ATI bioactivity determinations from flours and baked foods. ATI content is low or negligible in gluten free foods. Classification of grains and food products according to the amount of bioactive ATI (innate stimulating activity as determined by one of the bioassays).
Figure 9 shows ATIs in extracts from wheat flour on SDS PAGE gels (4-20% gradient). (A) Spring wheat extracted with acetic acid (AA) and subject to salting out using different concentrations of sodium chloride (NaCI). ATIs represent most of the band running in the 1 0-15kD range. Supernatant (s) and pellet (p) were treated with a without a reducing agent (dithiothreitol, dtt). Notably, in the acidic range ATIs are prominently precipitating between at 0.2 M NaCI, while at 0.5M NaCI gluten will precipitate (bands above the 25kD range). (B) Three different wheat samples extracted with ammonium bicarbonate (Abie) with or without reducing agent. Abie mostly extracts ATIs, with only minor amounts of gluten and other proteins.
Figure 10 shows determination of total ATI-quantity and ATI-species in different wheat extracts using mass spectrometry and relative amount of main ATIs in different extracts as well as other ATIs that include chymotrypsin inhibitor WCI, endogenous alpha-amylase/subtilisin inhibitor and CMX1 /CMX3.
Figure 11 shows relative quantity of ATI-species in different wheat extracts using mass spectrometry: (A) Abie extract, (B) chloroform/methanol (CM) extract, (C) commercial extract (1520), and (D) commercial extract(3535). Lyophilized ATI-extracts (Abie and chloroform-methanol) were reduced/alkylated, digested with trypsin and subjected to mass spectrometry.
Figure 12 shows relative quantity of the major ATI-species CM3 and 0.1 9 in different wheat extracts using mass spectrometry and Western blotting. (A and B) Determination of the percentage of CM3 and 0.1 9 relative to total protein in commercial extract 1520 and 3535 using mass spectrometry. (C)
Reducing SDS PAGE gel (4-20% gradient) and Western-blotting using rabbit peptide antibodies specific for CM3 and 0.19, respectively.
Figure 13 shows ATI bioactivity of fermented wheat dough. (A): ATI bioactivity in 90% wheat dough fermented with 1 0% rye malt. Samples were extracted with Abie, lyophilized and reconstituted.
Standardized extracts were cultured with the human monocytic cell line TH P-1 and cytokines secreted
(IL-8, MCP-1 and TNF-a) measured by ELISA. Bars in represent samples fermented with different strains (Lactobacillus sanfranciscensis (mutant), L. Sakei, L. Reuteri and L. Sanfranciscensis). Other bars represent a control sample of unfermented rye malt. Results are from 3-5 samples, and analysed for
sugnificance using one way ANOVA and compared against the unfermented sample (control) using Dunnett's test. Level of significance (p<0.05) was represented by asterisks. *p<0.05, **p<0.01 ,
***p<0.005. (B): ATI bioactivity of fermented dough prepared with 1 00% whole wheat. Samples were extracted with Abie and analyzed as described above (Fig.13A). Figure 14 shows inhibition of ATI-bioactivity using the natural TLR4-antagonist LPS-RS. TLR4-inhibitory lipopolysaccharide from Rhodobacter sphaeroides (LPS-RS, 1 .5 μg/ml_ ) was pre-incubated with THP-1 cells for 30 min, then ATIs enriched in CM3 and 0.1 9 (37^g/ml_) were added and cultured overnight. E.coli LPS (12.5ng/mL) was also cultured overnight with THP-1 cells pre incubated (30 min) with LPS-RS (250ng/mL). E.coli LPS (12.5ng/mL), LPS-RS (l^g/mL) or butter alone served as controls.
DETAILED DESCRIPTION OF THE INVENTION
Amylase trypsin inhibitors (ATIs)
Amylase trypsin inhibitors (ATIs) (as a term for all structurally and especially functionally related molecules) are molecules present in plants that act as triggers of innate immune activation. ATIs affect not only celiac disease activity but other inflammatory conditions.
The newly discovered activity of ATIs as nutritional activators of TLR4 is different from that of gluten in celiac disease and of wheat (rye, barley) proteins in allergy. ATIs can also act as inhalative allergens (Schuppan et al, Gastroenterology 2009; Batais et al, Eur Ann Allergy Clinic 2008; Catassi et al, Nutrients 2013; Uvackova et al, J Proteome Res 2013). Notably, the disease causing potency of ATIs ingested with wheat, barley, or rye (gluten-containing cereals) is not limited to the gastrointestinal tract, but is also likely implicated to affect other extraintestinal diseases (Tilg et al, Gastroenterology 201 3). We have accumulated broad evidence that nutritional ATIs induce low grade but significant inflammation in the small intestine and colon. Notably, nutritional ATIs exacerbate inflammatory diseases in general, as shown in mouse models of inflammatory bowel disease, of multiple sclerosis, and of allergic asthma. Figures 1 -4 demonstrate this "adjuvant effect" in the mentioned in vivo situations and diseases.
The methods of the invention can be performed in a variety of foodstuffs suspected of containing ATIs, including any food stuff having a cereal grain component (e.g., baked goods as described herein).
EXAMPLES
Example 1 - Methods to determine the (proinflammatory) bioactivity due to ATIs in unprocessed and processed foods
1. 1.Quantitative extraction of ATIs and proteolytic digestion of ATIs
Quantitative ATI extraction from different cereals, grains, and foods for determination of bioactivity
Buffer/solvent extractive method (applicable to most unprocessed foods, see sketch in Fig.5):
1 . Dried material is ground and sieved
2. 20 g are defatted with 200 ml methanol/diethylether 1 :1 for 2 h at 4-8 °C (stirring)
3. Centrifugation at 5.000 - 1 0.000 rpm for 1 0-30 min
Steps 2.-3 can also be omitted, without significant loss of bioactivity
4. Pellet is extracted with 200 ml of 50 mM ammonium bicarbonate (Abie) overnight at 4°C (stirring)
5. Centrifugation at 5.000 - 1 0.000 rpm for 1 0-30 min
6. Supernatant is freeze dried
7. Second (third) extraction as above
8. Combined supernatant is freeze-dried
9. Freeze dried material is reconstituted in e.g. 2 ml of PBS or cell culture compatible buffer or media
Other solvents such as chloroform/methanol (CM) can also be used, but they predominantly extract the more hydrophobic CM-class of ATIs, leaving other ATI species largely not extracted.
Sequential extraction using CM and the above solvents/buffers or vice versa is possible.
Buffers may vary in composition. Thus ammonium bicarbonate can also may be used in lower (e.g., 5 mM) or higher (e.g., 1 00 mM) concentrations, other neutral or slightly alkaline buffers can be used. Even acidic extraction is possible, e.g., by using 50 mM acetic acid. However acidic buffers co- extract significant amounts of other proteins such as gluten (further described in detail below).
Quantitative ATI extraction from further processed, e.g. cooked or baked foods such as bread, cookies, pasta or pizza
1 . Dried material is ground and sieved
2. 20 g are defatted with 200 ml methanol/diethylether 1 :1 for 2h at 4-8 °C (stirring)
3. Centrifugation at 5.000 - 1 0.000 rpm for 1 0-30 min
Steps 2.-3 can also be omitted, without significant loss of bioactivity
4. Pellet is digested with (gastrointestinal) proteases that do not significantly degrade the highly disulfide linked ATIs, such as pepsin followed by trypsin to better extract ATIs from the food matrix.
Proteolytic digestion of ATIs
Example of proteolytic digestion (pepsin-trypsin digestion protocol) can be found in Frazer et al, Lancet 1 959. A brief example is described below.
1 . 1 g of suspended sample is digested with pepsin (1 0 mg in 0.5 mL of 0.1 M HCL, pH 1 .8) at
37SC for 4 h.
2. Sample is centrifuged at 4,500 rpm for 1 0 min and the pellet is discarded.
3. Supernatant's pH is adjusted from 1 .8 to 7.8 with NaOH and then trypsin (Sigma T9201 , 1 0 mg in 0.5 mL neutral buffer, such as PBS) is added and incubated at 37SC for 4 h.
4. pH is adjusted to 4.5 with HCI and N-tosyl-chloromethyl-ketone (TLCK, 10 mg in 0.5 mL DMSO) is added to block the trypsin.
5. Precipitate is removed by centrifugation at 4,500 rpm for 1 0 min.
6. Pellet is discarded and supernatant is dialysed (molecular weight exclusion e.g. 1000 D) in 1 0 mM ammonium bicarbonate, Ph 7.8 (4L, 2 changes) at 4 SC.
7. Samples are sterile filtrated and freeze-dried.
8. Protein concentration may be determined by using a bicinchoninic acid protein assay (Pierce).
9. Freeze dried material is reconstituted in e.g. 2 ml of PBS or cell culture compatible buffer or media.
Other buffers and buffer and enzyme concentrations can be used, as long as enzyme activity is maintained. I n some, e.g., hardly baked, foods, more harsh conditions may be applicable. Also other enzymes such as chymotrypsin or thermolysin can be used exclusively (as neutral protease) or in combination with trypsin, since these can leave ATIs largely intact, while degrading other, major (cereal) proteins such as gluten (Camus and Laporte, Reprod Nutr Dev 1 980; Gessendorfer et al, Anal Bioanal Chem 2009; Jos et al, Scand J Gastroenterol 1975; Rombouts et al, Sci Rep 2013).
Due to their resistance to gastrointestinal proteases, ATIs remain largely intact after these proteolytic extraction procedures and maintain bioactivity. Our in vitro studies show that even with purified ATIs, the above-described digestion procedure reduces bioactivity by maximally 40%. Moreover, extracted bioactivity of 1 g of wheat flour before baking (10-20 min at 150-1 80SC) is reduced by maximally 50% post baking.
1.2 Bioactivity assays
Examples of bioactivity determinations are shown in Figs.6-8.
Cell culture
ATI extracts (freeze dried or centrifuged/concentrated) as described in Example 1 and reconstituted in cell-culture compatible buffers, are added to cultures of ATI-reactive (TLR4-bearing) cells, preferably monocytes/macrophages, dendritic cells, or cells transfected with the TLR4-M D2-CD14 oligomeric signaling complex. It is also preferable to use stable cell lines such as human TH P-1 , U937, or TLR4-M D2-CD14 transfected H EK-293 cells (obtainable e.g. from American Type Culture Collection). Apart from human cells, cells of other species such as mouse or rat can be used. Culture is preferably in complete RPMI or DMEM supplemented with 1 00 l U/ml penicillin/100 g/ml streptomycin and 10% fetal calf serum at 37 ^ in a 5% C02 atmosphere. Cells should be mycoplasma-free for reproducible results. Usually 1 -1 00 μΙ_ of the reconstituted extracts described in Example 1 are added to the cultures of the indicator cells (preferably seeded at densities of 25,000-200,000 cells in 0.2-1 ml_ medium in 24 well culture plates). Culture supernatants and/or cells are preferably harvested at 12-24 h post addition of the extracts to be tested.
Cytokine/chemokine assays.
The release of several chemokines and/or cytokines into the cell culture media due to addition of ATIs/ ATI extracts to the above cells can be quantified to serve as a quantitative measure of stimulatory ATI activity. Examples are IL-8, IL-15, TNFa, CCL2 (MCP-1 ), CCL5 (RANTES). This can be done using commercial validated ELISAs (e.g. IL-8 and TNFa [BD]; MCP-1 , IL-15, RANTES [R&D Systems]) according to the manufacturers' protocols. Apart from TLR4-dependent cytokines and chemokines, other secreted or cell extractable proteins/peptides downstream of TLR4 activation can be measured, including heat shock proteins (such as Hsp27, Hsp70, Hsp90) activation or known from the literature.
Use of cells transfected with TLR4-MD2-CD14 and an indicator gene
The lipopolysaccharide (LPS) receptor complex of TLR4, MD-2 and CD14 has been identified ATI-sensing receptor complex (Junker et al, J Exp Med 2012). Since I L-8 is a major cytokine induced by TLR4, a reporter cell line which stably expresses TLR4, M D-2 and CD14 proteins and the Renilla luciferase reporter gene under the transcriptional control of the IL-8 promoter was developed and is commercially available (R&D Systems, San Diego, CA; Lee et al 2013). We used this cell line to test ATI activity and compared values to those obtained with IL-8, MCP-1 and TNF-a release from ATI-stimulated TH P-1 cells (Fig.7). Other indicator systems that, e.g., generate fluorescent products or release soluble products that can be quantified in the cellular supernatant as described in Example 1 , or harbor other promoters that are driven by the activation of the TLR4-M D2-CD14 can also be used. These systems are particularly well suited for high throughput or high quantitative measurements of TLR4-complex stimulating ATI-activity.
Other assays for determination of ATI bioactivity
RNA isolation and quantitative RT-PCR
Total RNA is isolated from cells using e.g. TRIzol (I nvitrogen). Quantitative RT-PCR is preferably performed using exon-exon boundary-spanning primer sequences and e.g., the SYBR green or Taqman methodology as described for a set of cytokines by Junker et al (2012). Apart from TLR4-dependent cytokines and chemokines, other transcripts downstream of TLR4 activation can be measured, including heat shock proteins (such as Hsp27, Hsp70, Hsp90) but also other transcriptionally activated genes known from the literature.
Flow cytometry
After stimulation with extracted ATIs the above cells can also analyzed using flow cytometry that quantifies activation markers. Activation markers are e.g. CD80, CD86, MHC class I I, IL-12, IL-23, interferon gamma (intracellular stain) and many others known from the common literature. Cells are preincubated with FcR blocking reagent (Miltenyi Biotec) for 15 min at 4 °C before staining preferably with fluorescent-labeled monoclonal antibodies to these activation markers at predetermined concentrations for e.g. 30 min at 4 ^. Cells are then washed with staining buffer (e.g. PBS and 1 % BSA), cell viability is assessed by DAPI exclusion (0.1 pg/ml; Roche), and only viable cells are analyzed by flow cytometry using e.g. a four-laser LSRI I and FlowJo software (Tree Star) as described (Junker et al, J Exp Med 2012).
Altered signal transduction
Other quantitative readouts that can be used to measure ATI activity in samples are based on activation (or inhibition) of signaling pathways in the responsive cells. Examples are the phosphorylation of certain kinase substrates, such as I RF-3 or NFkB (p65), or N FkB nuclear translocation.
Lymphocyte proliferation assay
This method exploits the ability of TLR4-complex stimulated antigen presenting cells (such as monocytes, macrophages, dendritic or B cells) to permit proliferation or activation of antigen specific T cells in the presence of antigen. An example is the incubation of ovalbumin or gluten specific T cell lines or T cell clones, and HLA-compatible antigen presenting cells or cell lines loaded with ovalbumin (ova peptide) or gluten (gluten peptide), respectively. An (unknown amount of) ATI added to these cultures will dose-dependently stimulate T cell proliferation which can be measured in standard T cell proliferation
assays, using e.g. 3H-thymidine or BrdU incorporation. A simplified version of such assay is the addition of ATI-containing solutions to a classical mixed lymphocyter reaction with white blood cells of peripheral human or non-human, e.g. rodent, blood, or e.g., rodent splenocytes. Example 2 - Methods to determine the chemical quantity of ATIs in unprocessed and processed foods.
2.2 Quantitative extraction of ATIs from food
These methods permit another, even more thorough extraction of the highly proteolytically resistant ATIs (this resistance is mainly due to the presence of usually 5 intramolecular disulfide bridges), especially from processed, e.g., baked foods. Chemical quantification after reductive extraction is quantitative, but leads to loss of bioactivity due to unfolding of the proteins. However, this does not affect protein quantification. Extraction preferably uses reductive methods with or without detergents, and with or without additional proteolytic digestion.
These methods permit quantification of all ATI-species in a given cereal variant. Thus whole wheat genome sequencing revealed that modern hexaploid wheat contains up to 1 6 different ATI- species, and about half of these have been characterized as proteins. Moreover, ATIs represent between 2% and 4% of total wheat protein (with 80%-90% being gluten proteins). Importantly, ancient and older (diploid, tertraploid and early hexaploid) wheats contain fewer ATI genes and proteins (Altenbach et al, BMC Res Notes 201 1 ; Dupont et al, Proteome Sci 201 1 ). Finally, a second fertilization cycle (post anthesis fertilization) increases total protein content (mainly gluten), but decreases ATI content
(Altenbach et al., Proteome Sci 201 1 ). This is reflected by our bioactivity determinations shown below. We also show that the various ATI-variants display similar TLR4-stimulating bioactivity on a molar basis (see below).
Importantly, the other major gluten containing cereals (barley and rye) express various amylase/trypsin/chymotrypsin/subtilisin inhibitors with high sequence homology to the wheat ATIs
(Pekkarinen et al, J Agricult Food Chem 2003; Junker et al, J Exp Med 2012) and with similar overall TLR4-stimulating bioactivity (Fig.8).
Example: Reductive extraction of ATIs.
One gram of the (dried) food to be analyzed is extracted in neutral, near neutral or alkaline solvents/buffers, such as PBS, Tris-buffer, ammonium bicarbonate, preferably containing a detergent or detergent mixture (e.g., sodiumdodecyl sulfate, Triton X-100, Tween-20, sodium deoxycholate), and a reducing agent, such as 2-mercapto-ethanol, dithioerythritol (DTT), e.g. at 5-200 mM and at 37 ^ for 30 min to 4 hrs. For stabilization of free thiol groups, samples should be alkylated, e.g., with iodoacetamide at a final concentration of 20-500 mM for 1 0-60 min in the dark. Iodoacetamide will be quenched by excess reducing agents, e.g., 200 mM DTT. The cleared supernatant can be separated from small molecular weight contaminants e.g. by dialysis or ultrafiltration. For mass spectrometry the suspension (cleared supernatant) can be further digested, e.g., with trypsin.
For further analysis samples can be freeze-dried, concentrated in solution, e.g., by
ultracentrifugation, or protein can be adsorbed to a solid support. For mass spectrometry, peptides are preferably adsorbed to a solid support.
2.2 Quantification of extracted ATIs
Examples of chemical quantification of ATIs in flours are shown in Figs.9-12.
Mass spectrometry
This is preferentially performed in samples enriched in ATIs (quantitative extraction) and performed after proteolytic digest, using standard state of the art quantitatative MS techniques (Prandi B et al, Food Chem 2013). Liquid chromatography-mass spectrometry quantification of 4 different ATI isolates is shown in Fig.10-12.
Quantitative Western blotting
This is performed after reconstitution in appropriate buffers and by using poly- or monoclonal antibodies directed either to total ATIs or to all or major ATI species. This works best without proteolytic digest.
High titer antibodies have been produced against a mixture of ATIs extracted from hexaploid wheat and against several antigenic epitopes of major ATIs such as CM3, CM 16, 0.19 or 0.54. Examples of Western blot characterization are shown in Figs.12C.
Up to 16 ATI species have been described in what based on genetic analysis. However, a subset of ATIs usually represent >90% of all ATIs. These are noncovalently linked tetrameric CM2, CM3, CM1 6, dimeric 0.1 9, 0.54, and monomers of e.g. 0.1 9 and 0.54 (Altenbach et al, BMC Res Notes 201 1 ; Dupont et al, Proteome Sci 201 1 ). Our data indicate that TLR4-stimulatory ability as highest for di- and tetrameric ATIs and lowest for monomeric ATIs . Quantification of the major 3-8 ATI species in a given wheat, rye, or barley variant will approximate total ATI quantification. If desired, also the minor species can be quantified.
ELISA or similar quantitative assays
These work best both without and with (limited) proteolytic digest. They are based on monoclonal or polyclonal antibodies produced against antigenic (linear as well as structural epitopes of the major
ATIs). In ELISA one of the antibodies is bound to a solid phase, the other is linked to a detection system, such as biotin, alkaline phosphatase, peroxidase, fluorescent, or luminescent indicators, and state-of the art detection systems. This also includes assays based on inhibition which require, e.g., a coated antibody and a labeled ATI standard to compete with ATIs in the unknown sample. Other state of the art assays such as radioimmunoassays (equilibrium or inhibition format) or bead assays can also be used, including quantification by multiplexed assays.
Example 3 - Methods to prevent correct intramolecular disulfide formation in ATIs during grain growth or filling
The equilibrium between oxidized glutathione (GSSG) and protein bound glutathione (PSSG) shifts towards PSSG during the grain filling phase, e.g., the accumulation of storage proteins, mainly gluten (Bykova et al., Phytochem 201 1 ; Ferreira et al, Plant Physiol Biochem 201 2), prevents premature intra- and intermoleular disulfide bonding. Fixing the growing wheat plant in this redox state, characterized by PSSG will also prevent disulfide bonding within ATI molecules, and thus make the ATIs highly susceptible to denaturation and proteolytic degradation, either before or after further processing of the wheat flour. Similarly, excessive and continuous induction of the plant's early developmental
thioredoxin enzymatic system, also in conjunction with enhancement of PSSG complex formation, will keep nascent ATI molecules in the non-disulfide linked state, making them susceptible to proteolytic digestion (Wong et al, Phytochem 2004; Wong et al, Plant Cell Physiol 2004). These measures will also make wheat (rye, baley) flour more susceptible to proteolytic digestion in the human body.
Methods to promote the formation of PSSG bonds are cultivation with excess GSH or GSSG, the cultivation with or induction of enzymes that decrease the plant's redox potential such as superoxide dismutase or catalase activities. An alternative strategy is modulation of sulphur supply to the growing wheat (rye, barley), e.g., via use of sulphur rich vs. sulphur depleted fertilizers, also in sequence. Thus under sulphur depletion, resultant flour proteins including ATIs are more fixed in their disulfide structures and less susceptible to proteolytic degradation by external proteases or proteases if the gastrointestinal tract (Reinbold et al, J Agricult Food Chem 2008), although ATI content is (slightly) decreased.
Example 4 - Methods to remove ATIs or abolish ATI bioactivity from complex foods by thorough extraction from, e.g., wheat (rye, barley, or by fermentation and their ancestral grains) prior to introduction into the food chain
ATIs are quite resistant to degradation by many known proteases, including digestive enzymes of the human gastrointestinal tract such as pepsin, trypsin and chymotrypsin. Much of this resistance is due to the presence of several, usually five, intramolecular disulfide bonds that generate a compact secondary structure which is usually composed of four major alpha helices which are arranged up-and-down, securing a compact structure and hydrophobic interaction surfaces for di- and tetramerization (Oda et al, Biochemistry 1997). Useful methods to significantly decrease (>70%, preferably 80% and more) bioactive ATIs in e.g., flours are therefore based on 1 ) exhaustive extraction using preferably water based buffers, and 2) disulfide reduction which facilitates unfolding, eliminate bioactivity (i.e., activation of the TLR4-complex) and permit proteolytic digestion either before or during ingestion of the thus prepared foods. Proteolytic digestion of the reduced and unfolded ATIs can be achieved easily with common proteases used in the food industry, including e.g. , pepsin at acidic pH, or e.g. trypsin, chymotrypsin or subtilisin at near neutral or alkaline pH. Enzymes that degrade unfolded or denatured ATIs are also produced during certain fermentation processes, as described below, including sourdough fermentation or reductive fermentation. This also includes fermentations that produce specific enzyme activities to cleave (unfolded, denatured) ATIs, including bacteria that have been engineered to produce such activity for the food industry.
4.1 Chemical Methods (See also Figures.5, 6, and 9)
Solvent extraction of ATIs
ATIs can be extracted from flours and even processed foods using the methods described above
(1 .1 .1 and 1 .1 .2). Extraction with water-based buffers is preferable due to low costs and lack of potential toxicity of residual solvent. The extracted flour (food) can be separated mechanically, e.g., by sedimentation or centrifugation, and then freeze-dried or (preferably) dried in air or other (inert) gases that permit drying of bulk quantities. Before drying the pellet, other steps, such as washes with water and/or with (organic) solvents that have a lower boiling point than water but bind residual water, such as acetone, ethanol, or similar solvents used in the food industry can be used for removal of traces of salt or
acid (from the extraction buffer), and residual water. Residual water can also be retained when the extracted flour is frozen for storage and transport, or directly used for further food processing, such as fermentation or dough preparation.
Removal of 80-90% of bioactive ATIs can be reached with 1 -2 extractions, as detailed in Example 1 . This reduction would highly significantly reduce the risk of ATI-induced inflammation in the intestine and outside of the intestine in predisposed individuals, since nutritional ATI effects are dose dependent.
Chemical reduction of disulfides in ATIs.
These methods are similar to those detailed for analytical (quantitative) extraction of ATIs (described above). However, here the major aim is reductive inactivation of biologically active ATIs, in order to eliminate their TLR4 stimulatory activity, without toxicity to the consumer.
Example: Reductive inactivation of ATIs.
100 g of the (dried) flour or food is incubated in neutral, near neutral, or alkaline solvents/buffers, such as water or saline with pH adjustment, or with PBS and a reducing agent, such as cysteine, or glutathione (GSH) balanced with oxidized glutathione (GSSG), at temperatures that can range between 4°C and 1 00 °C, for times that can range between one second and 24 hrs. Other usually mildly reducing agents that are known in the food industry can also be used. Reduced ATIs are preferably denatured at temperatures above 50 °C and can be locked in this denatured state by disulfide linkage with, e.g., cysteine or GSH, or via mis-folded, newly generated, intra- and intermolecular disulfide bonds. Other free SH-group blocking agents used in the food industry can also be employed.
Fixation of partly reduced and thus severed intramolecular disulfides in ATIs can also be brought about during dough mixing by the addition of vitamin C or other pro-oxidative systems that generate, e.g., activated oxygen. This has been demonstrated for disulfides in glutenins (Koehler P et al, J Agricult Food Chem 2003a and b), but is also effective in ATIs.
4.2 Fermentation strategies to decrease bioactive ATI in foods such as flours
There are several fermentation methods that reduce ATI bioactivity, largely being based on non- reductive or reductive fermentation and/or proteolytic digestion of (disulfide reduced) ATIs.
Fermentation of wheat (rye, barley) dough with lactobacilli is used to enhance the degradation of gluten proteins under acidic conditions. Select lactobacilli that have an active thiol (disulfide reducing) metabolism are particularly suited to reduce and subsequently degrade ATIs proteolytically. An example are Lactobacillus reuteri and L. sanfranciscensis which efficiently deactivate proteins such as the highly disulfide linked ovotransferrin of wheat as well as ATIs. Proteolytic activity is mainly brought about by wheat aspartic acid proteases (Loponen et al, J Ag ricult Food Chem 2007; Loponen et al, J Agricult Food Chem 2008), but other proteolytic enzymes used in the food industry can be added. Fermentation of wheat flour and other ATI-containing flours can be done e.g. with varying proportions of rye malt in the dough, such as 5-20%. Here, apart from adding beneficial bacteria that are used in the food industry to prepare e.g. sourdough (Lactobacillus species), rye malt serves as source of proteolytic enzymes that were shown to degrade immunogenic gluten proteins (Loponen et al, J Agricult Food Chem 2007). This method can be combined with any of the other ATI-reducing methods described herein.
Reduction of ATI content by non-reductive and reductive fermentation of ATI-containing flours and doughs
The doughs can be prepared with whole wheat flour and without additives. Optimization is possible using refined instead of crude flours, or addition of common agents that are used in the food industry to improve fermentation or dough quality. An example is the addition of reducing agents, such as cysteine or glutathione, either before, during or after fermentation. Another alternative is the use of fermenting bacteria with high disulfide reducing ability. Such strains have been described and comprise, e.g., Lactobacillus sanfranciscensis and L. reuteri LTH2584. Fig.13 shows the results of fermentation experiments (24 hrs) performed. ATI activity was determined in two sequential combined ammonium bicarbonate extractions from the fermented and then frozen doughs, using the methodology described above.
The following fermentation protocols were applied for 24 hrs at 37°C:
i) chemically acidified control (low SH (sulfhydryl)-levels in dough, no reduction of disulfide bonds in proteins);
ii) Lactobacillus sakei (low SH);
iii) Lactobacillus sanfranciscensis (high SH-levels in dough and reduction of disulfide bonds in proteins owing to glutahione reductase activity);
iv) Lactobacillus sanfranciscensis delta gsrH (low SH-levels in dough as gene coding for glutathione reductase gene was disrupted) ;
v) Lactobacillus reuteri LTH2584 (high SH-levels owing to cystathionine gamma lyase);
vi) a second chemically acidified control to match the growth temperature of L. reuteri.
Controls for appropriate fermentation: Doughs were analysed with respect to pH, organic acid levels and SH-groups, as were the numbers of fermenting bacteria. The data demonstrate an up to -50- 60% reduction in ATI-bioactivity in the sourdoughs that were fermented with Lactobacilli in general, either with or without rye malt addition. This indicates significant proteolytic digestion and thus inactivation of ATIs by fermentation in general, without higher degradation activity by disulfide reducing strains.
Notably, an advantage of the thiol-reducing bacteria (L. sanfranciscensis and L. reuteri) is likely. In a preliminary experiment, post fermentation heating of the dough to elevated temperatures that do not yet inactivate the rye (barley) malt or Lactobacillus-derived proteolytic enzymes (time up to 2 hrs) could further reduce ATI bioactivity down to 20% in the doughs subject to thiol reducing Lactobacilli vs. 30% in the non-thiol-reducing bacteria, indicating an advantage of the former strains. This was accompanied by a comparable reduction of major ATI-bands CM3 and 0.19 in a Western blot using our polyclonal antibodies specific for these protein. Overall, reductive fermentation more than conventional fermentation leads to disulfide reduction of ATIs which then become susceptible to proteolytic degradation by enzymes used in the food industry, such as those produced by Lactobacillae or that are present in malt.
Example 5 - TLR4 antagonistic compounds that can be added to ATI containing foods
There are several (weak to moderately active) oral TLR4 antagonists, many of them of herbal origin, with long-term use as spices or food additives. These are e.g. alkaloids, aromatic compounds, polyphenols, peptides or proteins (Rossignal and Lynn 2005; Lucas and Maes, Mol Neurobiol 2013). Examples include, but are not limited to, Bartonella quintana lipopolysaccharide (Popa et al, Infect
Immunol 2007); extracts of leaves from Clerodendrum (Kouakou et al, BMC Complement Altern Med 2013); cinnamon extract and its active components (Kanuri et al, J Nutr 2009); eritoran mimicking the MD component of the TLR4-M D2-CD14 complex, formulated to be resistant to gastric or intestinal hydrolysis (Shirey et al, Nature 2013); epigallocatechin-3-gallate from, e.g., green tea (Hong et al, J Immunol 201 0; Bao et al, Mol Nutr Food Res 2013) ; 6-shogaol and 1 -dehydro-1 0-gingerdione (1 D1 0G) from Ginger (Ahn et al, Mol Cless 2009; Park et al, Biochem Biophys Res Communic 2012); Melatonin (Hu et al, Pinela Res 2013); Berberin as TLR4-N FkB pathway inhibitor (Li et al, Acta Pharmacol Sin 2012); Lipopolysaccharide from the photosynthetic bacterium Rhodobacter sphaeroides (LPS-RS) (Rallabhandi et al, Coats et al, J Immunol 2005); and Lipopolysaccharide from Porphyromonas gingivalis (Coats et al, J Immunol 2005; Curtis et al, Infect Immunol 201 1 )
Adding these compounds or compound mixtures with proven TLR4 antagonistic activity to ATI- containing foods will antagonize the TLR4-activating activity of ATIs, without need of prior extraction or inactivation. This should be relevant to either completely avoid these prior inactivation or extraction steps, or to "neutralize" residual ATI activity after these steps. We could demonstrate that this neutralization of ATI-induced innate immune activation by using the natural TLR4-antagonist from the photosynthetic bacterium Rhodobacter sphaeroides (LPS-RS) (Rallabhandi et al, J Immunol 2005)
(Fig.14).
OTHER EMBODIMENTS
All publications, patents, and patent applications mentioned in the above specification are hereby incorporated by reference to the same extent as if each individual publication, patent or patent application was specifically and individually indicated to be incorporated by reference in its entirety. Various modifications and variations of the described devices and methods of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with specific embodiments, it will be understood that it is capable of further modifications and that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention that are obvious to those skilled in the art are intended to be within the scope of the invention. This application is intended to cover any variations, uses, or adaptations of the invention following, in general, the principles of the invention and including such departures from the present disclosure come within known customary practice within the art to which the invention pertains and may be applied to the essential features herein before set forth.
Other embodiments are within the following claims.
Claims
1 . A method of reducing the ATI content of a foodstuff, said method comprising incubating said foodstuff in an extraction buffer for a duration sufficient to reduce the ATI content of said foodstuff by at least 50% followed by removing said extraction buffer from said foodstuff.
2. The method of claim 1 , wherein said extraction buffer is a neutral, near neutral, or alkaline solvent or buffer.
3. The method of claim 2, wherein said extract buffer is selected from the group consisting of PBS, Tris- buffer, water, and ammonium bicarbonate.
4. The method of claim 2 or 3, wherein said extract buffer further comprises a detergent or detergent mixture.
5. The method of claim 4, wherein said detergent or detergent mixture is selected from the group consisting of sodiumdodecyl sulfate, Triton X-100, Tween-20, sodium deoxycholate.
6. The method of any one of claims 1 -5, wherein said extraction buffer further comprises a reducing agent.
7. The method of claim 6, wherein said reducing agent is selected from the group consisting of - mercapto-ethanol, dithioerythritol (DTT), cysteine, or glutathione (GSH) balanced with oxidized glutathione (GSSG).
8. The method of any one of claims 1 -7, wherein said alkylating agent is iodoacetamide and said alkylating agent is further quenched by the addition of access reducing agent.
9. The method of any one of claims 1 -8, wherein said foodstuff is separated mechanically prior to said incubation.
10. The method of claim 9, wherein said mechanically separated foodstuff is dried prior to said incubation.
1 1 . The method of claim 1 0, wherein said drying is air-drying or freeze drying.
12. The method of claim 1 0 or 1 1 , wherein, prior to said drying, said mechanically separated foodstuff is contacted with an aqueous solvent or an organic solvent having a lower boiling point than water.
13. The method of claim 12, wherein said organic solvent is selected from the group consisting of acetone or ethanol.
14. A method of extracting amylase trypsin inhibitors (ATIs) from a foodstuff, said method comprising:
A. incubating said foodstuff with an extraction buffer in a mixture;
B. centrifuging said mixture to form a pellet and supernatant;
C. drying said supernatant; and
D. reconstituting the dried supernatant in a reconstitution buffer; wherein extracted ATIs are present in said reconstitution buffer.
15. The method of claim 14, wherein said foodstuff is unprocessed prior to extraction.
16. The method of claim 14, wherein said foodstuff is a processed foodstuff.
17. The method of any of claims 14-1 6, wherein, prior to step A, said foodstuff is ground.
18. The method of any of claims 14-1 7, wherein, prior to step A, said foodstuff is defatted.
19. The method of claim 1 8, wherein said defatting is performed by the incubation of said foodstuff with methanol/diethylether.
20. The method of claim 1 9, wherein said methanol/diethyl ether is present at a 1 :1 ratio.
21 . The method of any of claims 1 -20, wherein said extraction buffer is ammonium bicarbonate, chloroform/methanol, or an acid.
22. The method of claim 21 , wherein said acid is acetic acid.
23. The method of claim 21 or 22, wherein said extraction buffer is at a concentration between 5 mMol to 100 mMol.
24. The method of any of claims 14-23, wherein said drying is freeze-drying or drying under a stream of gas, e.g., air.
25. The method of any of claims 14-24, wherein steps A-C are repeated prior to step D.
26. The method of claim 25, wherein the extraction buffer in steps A-C is first chloroform/methanol and the extraction buffer is ammonium bicarbonate when steps A-C are repeated or wherein the extraction buffer is ammonium bicarbonate in both extractions.
27. The method of any of claims 14-26, wherein, prior to step A, the foodstuff is digested with a protease.
28. The method of claim 27, wherein said protease is pepsin, trypsin, chymotrypsin, and/or thermolysin.
29. The method of claim 28, wherein said foodstuff is first digested with pepsin followed by digestion with trypsin.
30. The method of any of claims 27-29, wherein, after the foodstuff is digested with a protease, the foodstuff is centrifuged to form a supernatant and said supernatant is incubated with the extraction buffer of step A.
31 . The method of claim 30, wherein said incubation is performed as a dialysis incubation, step B is omitted, and said supernatant, after dialysis is dried in step C.
32. A method of determining the bioactivity of ATIs in a sample, said method comprising incubating ATI- reactive cells with an extract suspected of comprising ATIs and determining an ATI-response in said ATI- reactive cells, thereby determining the bioactivity of said ATIs in a sample.
33. The method of claim 32, wherein said extract suspected of comprising ATIs is prepared by the method of any one of claims 1 -1 8.
34. The method of claim 32 or 33, wherein said ATI-reactive cells express TLR4.
35. The method of any one of claims 32-34, wherein said ATI-reactive cells are selected from the group consisting of monocytes/macrophages, dendritic cells, or cells transfected with a TLR4-MD2-CD14 oligomeric signaling complex.
36. The method of claim 35, wherein said cells are stable cell lines selected from the group consisting of THP-1 and U937 cells.
37. The method of any of claims 32-36, wherein said determination of ATI-response comprises quantification of one or more cytokines released by said cells.
38. The method of claim 37, wherein said one or more cytokines are selected from the group consisting of IL-8, IL-15, TNFa, CCL2 (MCP-1 ), and CCL5 (RANTES).
39. The method of claim 37 or 38, wherein said quantification is performed by ELISA.
40. The method of any one of claims 32-36, wherein said cell comprises a reporter gene under the control of a TLR4 (ATI)-responsive promoter and said determination of an ATI-response comprises detection of expression of said reporter gene.
41 . The method of claim 40, wherein said ATI-responsive promoter is the IL-8 promoter.
42. The method of claim 40 or 41 , wherein said reporter gene encodes a luminescent or fluorescent protein.
43. The method of any one of claims 32-36, wherein said determination of ATI-response comprises measuring a level of one or more RNAs in said cells associated with an ATI-response.
44. The method of claim 43, wherein said one or more RNAs corresponds to Hsp27, Hsp70, and/or Hsp90.
45. The method of any one of claims 32-36, wherein said determination of ATI-response comprises detecting one or more activation markers on or in said cells.
46. The method of claim 45, wherein said one or more activation markers is selected from the group consisting of CD80, CD86, M HC class I I, IL-12, IL-23, and interferon gamma (release or intracellular stain).
47. The method of claim 45 or 46, wherein said detecting comprises flow-cytometry.
48. The method of any one of claims 32-36, wherein said determination of ATI-response comprises detecting an alteration is a signaling pathway associated with an ATI response.
49. The method of claim 48, wherein said alteration in a signaling pathway is detected based on the detection of I RF-3, NFkB (p65), or N FkB nuclear translocation.
50. The method of any one of claims 32-36, wherein said determination of ATI-response comprises contacting ovalbumin or gluten specific T cells in the presence of said sample suspected of containing ATIs and measuring the proliferation of said cells in the presence of ATI-reactive antigen presenting cells.
51 . A method of quantifying the amount of ATIs in a foodstuff, said method comprising: incubating said foodstuff in an extraction buffer thereby forming an extract; optionally incubating said extract with an alkylating agent; separating the ATIs from said extract; and quantifying said separated ATIs.
52. The method of claim 51 , wherein said extraction buffer is a neutral, near neutral, or an alkaline solvent or buffer.
53. The method of claim 52, wherein said extract buffer is selected from the group consisting of PBS, Tris-buffer, ammonium bicarbonate.
54. The method of claim 52 or 53, wherein said extract buffer further comprises a detergent or detergent mixture.
55. The method of claim 54, wherein said detergent or detergent mixture is selected from the group consisting of sodium dodecyl sulfate, Triton X-100, Tween-20, sodium deoxycholate.
56. The method of any one of claims 51 -55, wherein said extraction buffer further comprises a reducing agent.
57. The method of claim 56, wherein said reducing agent is selected from the group consisting of mercapto-ethanol or dithioerythritol (DTT).
58. The method of any one of claims 51 -57, wherein said alkylating agent is iodoacetamide and said alkylating agent is further quenched by the addition of access reducing agent.
59. The method of any of claims 51 -58, wherein said method further comprises adding a protease to said extract.
60. The method of claim 59, wherein said protease is trypsin.
61 . The method of any of claims 51 -60, wherein said ATIs are quantified by mass spectrometry, quantitative western blotting, or ELISA.
62. A method of reducing the reactivity of a foodstuff, said method comprising cultivating a cereal with oxidized glutathione (GSSG) and/or protein bound glutathione (PSSG).
63. A method of reducing the reactivity of a foodstuff, said method comprising cultivating a cereal with sulfur rich or sulfur depleted fertilizers.
64. A method of reducing the ATI content of a foodstuff, said method comprising fermenting said foodstuff with a bacteria with high disulfide reducing ability.
65. The method of claim 64, wherein said bacteria is selected from the group consisting of Lactobacillus sanfranciscensis and L. reuteri LTH2584.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/308,397 US20170049136A1 (en) | 2014-05-02 | 2015-04-30 | Methods for determination of bioactivity, removal, or inactivation cereal amylase trypsin inhibitors in cereals, flours and complex foods |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461987884P | 2014-05-02 | 2014-05-02 | |
US61/987,884 | 2014-05-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2015168416A1 true WO2015168416A1 (en) | 2015-11-05 |
Family
ID=54359333
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2015/028535 WO2015168416A1 (en) | 2014-05-02 | 2015-04-30 | Methods for determination of bioactivity, removal, or inactivation cereal amylase trypsin inhibitors in cereals, flours and complex foods |
Country Status (2)
Country | Link |
---|---|
US (1) | US20170049136A1 (en) |
WO (1) | WO2015168416A1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017075456A1 (en) * | 2015-10-30 | 2017-05-04 | Beth Israel Deaconess Medical Center, Inc. | Methods for determination of bioactivity, quantity, removal, or inactivation of cereal amylase trypsin inhibitors in cereals, flours, plants, and complex foods |
DE102017122407A1 (en) | 2017-09-27 | 2019-03-28 | Ernst Böcker Gmbh & Co. Kg | Compatible flour composition |
WO2021226672A1 (en) | 2020-05-12 | 2021-11-18 | Glutagen Pty Ltd | Methods and compositions for ati digestion |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110208448A (en) * | 2019-04-28 | 2019-09-06 | 北京谷海天目生物医学科技有限公司 | Protein group sample processing reagent box, processing method and application |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6113951A (en) * | 1991-10-12 | 2000-09-05 | The Regents Of The University Of California | Use of thiol redox proteins for reducing protein intramolecular disulfide bonds, for improving the quality of cereal products, dough and baked goods and for inactivating snake, bee and scorpion toxins |
US20030135878A1 (en) * | 1999-03-29 | 2003-07-17 | Myeong-Je Cho | Transgenic plants with elevated thioredoxin levels |
KR20120121717A (en) * | 2011-04-27 | 2012-11-06 | 대한민국(관리부서:농촌진흥청장) | Manufacturing Method of Healthy Bread Comprising Unhulled Red-Line Sorghum Powder |
US20130266584A1 (en) * | 2010-04-30 | 2013-10-10 | Detlef Schuppan | Methods and compositions for treating celiac disease |
-
2015
- 2015-04-30 US US15/308,397 patent/US20170049136A1/en not_active Abandoned
- 2015-04-30 WO PCT/US2015/028535 patent/WO2015168416A1/en active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6113951A (en) * | 1991-10-12 | 2000-09-05 | The Regents Of The University Of California | Use of thiol redox proteins for reducing protein intramolecular disulfide bonds, for improving the quality of cereal products, dough and baked goods and for inactivating snake, bee and scorpion toxins |
US20030135878A1 (en) * | 1999-03-29 | 2003-07-17 | Myeong-Je Cho | Transgenic plants with elevated thioredoxin levels |
US20130266584A1 (en) * | 2010-04-30 | 2013-10-10 | Detlef Schuppan | Methods and compositions for treating celiac disease |
KR20120121717A (en) * | 2011-04-27 | 2012-11-06 | 대한민국(관리부서:농촌진흥청장) | Manufacturing Method of Healthy Bread Comprising Unhulled Red-Line Sorghum Powder |
Non-Patent Citations (2)
Title |
---|
JUNKER, Y ET AL.: "Wheat amylase trypsin inhibitors drive intestinal inflammation via activation of toll-like receptor 4.", J. EXPERIMENTAL MEDICINE, vol. 209, no. 13, 3 December 2012 (2012-12-03), pages 2395 - 2408, XP055082901, Retrieved from the Internet <URL:http://jem.rupress.org/content/209/13/2395.full.pdf+html> [retrieved on 20150629] * |
PRANDI, B ET AL.: "LC/MS analysis of proteolytic peptides in wheat extracts for determining the content of the allergen amylase/trypsin inhibitor CM3: Influence of growing area and variety.", FOOD CHEMISTRY., vol. 140, 2013, pages 141 - 146, XP028530095, Retrieved from the Internet <URL:http://www.researchgate.net/profile/Gianni_Galavema2/publication/236195144_LCMS_analysis_of_proteolytic_peptides_in_wheat_extracts_for_determining_the_content_of_the_allergen_amylasetrypsin_inhibitor_CM3_Influence_of_growing_area_and_variety/links/02e7e5229e8e3e9bc9000000.pdf> [retrieved on 20150629] * |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017075456A1 (en) * | 2015-10-30 | 2017-05-04 | Beth Israel Deaconess Medical Center, Inc. | Methods for determination of bioactivity, quantity, removal, or inactivation of cereal amylase trypsin inhibitors in cereals, flours, plants, and complex foods |
CN108697116A (en) * | 2015-10-30 | 2018-10-23 | 贝丝以色列女执事医疗中心 | For measuring the bioactivity of the cereal starch enzyme trypsin inhibitor in cereal, flour, plant and complex food, amount, removing or the method for inactivation |
EP3367812A4 (en) * | 2015-10-30 | 2019-06-26 | Beth Israel Deaconess Medical Center, Inc. | Methods for determination of bioactivity, quantity, removal, or inactivation of cereal amylase trypsin inhibitors in cereals, flours, plants, and complex foods |
AU2016343738B2 (en) * | 2015-10-30 | 2021-05-13 | Beth Israel Deaconess Medical Center, Inc. | Methods for determination of bioactivity, quantity, removal, or inactivation of cereal amylase trypsin inhibitors in cereals, flours, plants, and complex foods |
US11291221B2 (en) | 2015-10-30 | 2022-04-05 | Beth Israel Deaconess Medical Center, Inc. | Methods for determination of bioactivity, quantity, removal, or inactivation of cereal amylase trypsin inhibitors in cereals, flours, plants, and complex foods |
DE102017122407A1 (en) | 2017-09-27 | 2019-03-28 | Ernst Böcker Gmbh & Co. Kg | Compatible flour composition |
WO2019063721A1 (en) | 2017-09-27 | 2019-04-04 | Ernst Böcker Gmbh & Co. Kg | Well-tolerated flour composition |
WO2021226672A1 (en) | 2020-05-12 | 2021-11-18 | Glutagen Pty Ltd | Methods and compositions for ati digestion |
Also Published As
Publication number | Publication date |
---|---|
US20170049136A1 (en) | 2017-02-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2016343738B2 (en) | Methods for determination of bioactivity, quantity, removal, or inactivation of cereal amylase trypsin inhibitors in cereals, flours, plants, and complex foods | |
Zevallos et al. | Nutritional wheat amylase-trypsin inhibitors promote intestinal inflammation via activation of myeloid cells | |
Scherf et al. | Novel approaches for enzymatic gluten degradation to create high-quality gluten-free products | |
De Angelis et al. | Fermentation by selected sourdough lactic acid bacteria to decrease coeliac intolerance to rye flour | |
Spaenij–Dekking et al. | Natural variation in toxicity of wheat: potential for selection of nontoxic varieties for celiac disease patients | |
Shan et al. | Identification and analysis of multivalent proteolytically resistant peptides from gluten: implications for celiac sprue | |
Tanabe | Analysis of food allergen structures and development of foods for allergic patients | |
US20170049136A1 (en) | Methods for determination of bioactivity, removal, or inactivation cereal amylase trypsin inhibitors in cereals, flours and complex foods | |
Carroccio et al. | Searching for wheat plants with low toxicity in celiac disease: between direct toxicity and immunologic activation | |
CN102430111A (en) | Epitopes related to coeliac disease | |
Elli et al. | Immunological effects of transglutaminase-treated gluten in coeliac disease | |
Capozzi et al. | Modulatory effect of gliadin peptide 10-mer on epithelial intestinal CACO-2 cell inflammatory response | |
Comino et al. | Significant differences in coeliac immunotoxicity of barley varieties | |
Caputo et al. | Enzymatic strategies to detoxify gluten: implications for celiac disease | |
ES2402014A1 (en) | Peptide secreted by lactobacillus plantarum with immunomodulating function | |
Lafarga et al. | Addition of an enzymatic hydrolysate of bovine globulins to bread and determination of hypotensive effects in spontaneously hypertensive rats | |
Jayawardana et al. | Possibility of minimizing gluten intolerance by co-consumption of some fruits–A case for positive food synergy? | |
JP2021073236A (en) | Composition and method for treating gluten intolerance and disorder arising therefrom | |
Marino et al. | The effects of modified versus unmodified wheat gluten administration in patients with celiac disease | |
ES2821771T3 (en) | Treatment of gluten intolerance and related conditions | |
Vincentini et al. | Gliadin-dependent cytokine production in a bidimensional cellular model of celiac intestinal mucosa | |
Luongo et al. | Tailoring the immune response to wheat gliadin by enzymatic transamidation | |
Iacomino et al. | Triticum monococcum amylase trypsin inhibitors possess a reduced potential to elicit innate immune response in celiac patients compared to Triticum aestivum | |
ITMI20062080A1 (en) | TREATMENT OF CEREAL FLOURS FOR FOOD CONSUMPTION BY CELIAC PATIENTS | |
Mamone et al. | Analytical and functional approaches to assess the immunogenicity of gluten proteins |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15786628 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15308397 Country of ref document: US |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 15786628 Country of ref document: EP Kind code of ref document: A1 |